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Toxoplasma Modulates Signature
Pathways of Human Epilepsy,
Neurodegeneration & Cancer
Huân M. Ngô1,2,3, Ying Zhou1, Hernan Lorenzi4, Kai Wang5, Taek-Kyun Kim5, Yong Zhou5, Kamal El
Bissati1, Ernest Mui1, Laura Fraczek 1, Seesandra V. Rajagopala4, Craig W. Roberts 6, Fiona L.
Henriquez1,16, Alexandre Montpetit7, Jenefer M. Blackwell8,9, Sarra E. Jamieson9, Kelsey Wheeler1,
Ian J. Begeman1, Carlos Naranjo-Galvis 1, Ney Alliey-Rodriguez 1, Roderick G. Davis10,
Liliana Soroceanu11, Charles Cobbs11, Dennis A. Steindler12, Kenneth Boyer13, A. Gwendolyn
Noble2, Charles N. Swisher2, Peter T. Heydemann13, Peter Rabiah14, Shawn Withers1, Patricia
Soteropoulos15, Leroy Hood5 & Rima McLeod1
One third of humans are infected lifelong with the brain-dwelling, protozoan parasite, Toxoplasma
gondii. Approximately fifteen million of these have congenital toxoplasmosis. Although
neurobehavioral disease is associated with seropositivity, causality is unproven. To better understand
what this parasite does to human brains, we performed a comprehensive systems analysis of the
infected brain: We identified susceptibility genes for congenital toxoplasmosis in our cohort of infected
humans and found these genes are expressed in human brain. Transcriptomic and quantitative
proteomic analyses of infected human, primary, neuronal stem and monocytic cells revealed effects
on neurodevelopment and plasticity in neural, immune, and endocrine networks. These findings were
supported by identification of protein and miRNA biomarkers in sera of ill children reflecting brain
damage and T. gondii infection. These data were deconvoluted using three systems biology approaches:
“Orbital-deconvolution” elucidated upstream, regulatory pathways interconnecting human
susceptibility genes, biomarkers, proteomes, and transcriptomes. “Cluster-deconvolution” revealed
visual protein-protein interaction clusters involved in processes affecting brain functions and circuitry,
including lipid metabolism, leukocyte migration and olfaction. Finally, “disease-deconvolution”
identified associations between the parasite-brain interactions and epilepsy, movement disorders,
Alzheimer’s disease, and cancer. This “reconstruction-deconvolution” logic provides templates of
progenitor cells’ potentiating effects, and components affecting human brain parasitism and diseases.
The first half of the 20th century achieved remarkable advances in control of some communicable diseases, with
development of immunizations, antimicrobial therapies, and increasing ability to identify new pathogenic organisms1. The second half shifted to understanding chronic degenerative diseases as prevailing causes of death in
older populations. One primary challenge for contemporary medicine is to control non-communicable diseases
with complex gene-environment etiologies and progression2, 3, postulated to arise from complex interactive cascades of genetic and environmental factors. Historical efforts to find causes and cures for such illnesses, including
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brain diseases, have had a glaring omission of a significant environmental factor: Over 2 billion humans are
infected with the neurotrophic parasite Toxoplasma gondii. Congenital and postnatal infections with T. gondii persist in all infected persons. The parasite interconverts between slow-growing, encysted bradyzoites and
rapid-growing tachyzoites4. In mice, T. gondii creates a chronic intra-neuronal infection and an inflammatory
process4. Mice with acute and chronic infection have alterations in neurotransmitters, memory, seizures, and
neurobehaviors5, 6. Some epidemiologic-serologic studies show associations between seropositivity for T. gondii
and human neurologic diseases, for example, Parkinson’s and Alzheimer’s diseases7, 8. Serologic studies of humans
with diverse genetics are not optimal to detect strong associations or directionality. Epidemiologic associations
also do not reveal parasite-modulated gene networks in human brain that could provide insights into how to cure
and prevent resultant diseases. We need integrative approaches to examine relationships between brain parasitism
and other brain diseases9, 10, to provide a foundation to identify key pathways and molecules for drug and vaccine
design.
To address these problems, we considered two central questions: (i) If chronic brain parasitism associates
with other neurologic diseases, what are they? and (ii) Which macromolecular networks are modulated by the
parasite in human brain that lead to neuropathology which could underpin and facilitate design of treatments?
We hypothesized that a systems approach integrating multiple levels of host parasite interactions might resolve
these questions. To gain insights into relationships between human T. gondii infections and brain disorders, we
studied a unique cohort, the National Collaborative Chicago Based Congenital Toxoplasmosis Study (NCCCTS),
and identified human susceptibility genes, as well as serologic biomarkers of active brain disease. The NCCCTS
has diagnosed, treated and followed 246 congenitally infected persons and their families continuously beginning
in 198111–39. Next in our study, we obtained new transcriptomic and proteomic data from infections of primary,
human, neuronal stem cells, and monocytic cells that infiltrate brain, to determine whether there are different
phenotypic effects of Type I, II, or III T. gondii tachyzoites. We used these four data sets to construct an integrated
molecular model of the infected human brain. In a second phase, the model was further analyzed using systems
biology approaches to provide insights into the molecular mechanisms by which T. gondii infection may cause
disease. The broader goal was to provide a robust database and informatic analysis for the scientific community
to use for their research. This report described only a limited number of important observations. This effort to
integrate multiple levels of intrinsic and extrinsic factors offers an original template to unravel pathogenesis of
complex diseases in humans.
Our studies presented here were performed to examine genetic and parasite effects we hypothesized would
influence outcomes (Fig. 1a). We utilized a novel systems approach expanding from gene-environment paradigms
to include a third component of development (Fig. 1a). In Fig. 1a, there is intersection/overlap between the circles
representing components of the host-parasite interactions. These circles include host-parasite genetics, toxoplasmosis susceptibility genes, and serum biomarkers in children in the NCCCTS [T. gondii infection, red circle],
human neuronal stem cell functional assays including transcriptomics and proteomics [Brain pathology mechanisms, blue circle], and disease pathogenesis/pathology susceptibility genes for other diseases [others, green
circle]). This overlap/intersection in the Venn diagram indicates the circumstances in which we hypothesize that
manifestations of other diseases will occur. To test this hypothesis, we isolated the infected brain as a system. This
sequence of our work presented herein, and structure of our studies, and these results are shown in a flow chart
(Fig. 1b), detailed outline (Fig. 1c), and schematic diagram of our model created based on this work (Fig. 1a and d).
The overall plan was to gain access to the network interactome and biosignatures of T. gondii and the human
brain, which first reconstructed the T. gondii brain infection. Our first steps of reconstructing T. gondii brain
infection included discovery, integration and systems analysis of our original data. These systematic analyses
of our novel human data sets used empiric studies of human T. gondii infections of persons with toxoplasmosis
and their families, and infectomes of primary, human brain stem and monocytic cells (Fig. 1b,c). In our work,
the human infectome is defined as the human host and parasite molecules, and pathways that are perturbed by
the interaction of the human host and parasite T. gondii, as has been characterized by others for studies of other
pathogens in earlier literature. An interactome is the whole set of molecular interactions such as protein-protein
and genetic interactions. This can provide a global “Omic” view of molecular effects as in the resource APID interactome (http://cicblade.dep.usal.es:8080/APID/init.action). To our knowledge, this study herein is the only single
human cohort that is directly observed by a uniform group of examiners, longitudinally in a variety of ways,
combined with human, primary, neuronal stem cell Omics Systems analysis for the T. gondii infectome, then
interrogated for disease susceptibility genes/proteins. We obtained cellular data to test a few pathways relevant to
pathogenesis. These first were considered individually and then together to determine whether we identified key
biologic processes and biosignatures affected by T. gondii. Second, the integrated brain infectome became a global
map that was deconvoluted to determine functional clusters and disease correlates (Fig. 1d). We termed this
approach “Reconstruction and Deconvolution” (Fig. 1d). Specifically, Reconstruction was based on our unique
cohort of infected persons, most of whom showed neuropathologic symptoms13, to identify novel human genetics of susceptibility to toxoplasmosis. Then, serologic biomarkers were studied for a limited number of infected
humans to assay readout of an infected brain. We selected neural stem cells to uncover potential developmental
mechanisms because of their multipotency central to neurodevelopment and neuroplasticity. Most brain diseases result from abnormal neurodevelopment (e.g., epilepsy) and neuroplasticity (e.g., neurodegeneration).
Hence, transcriptomic and proteomic infectomes of human neural stem cells were studied for parasite effects
using primary cultures of cells from the hippocampus-temporal lobe. These datasets were integrated into a total
brain infectome. They were unraveled, or “deconvoluted”, to identify functional and disease correlates. This was
accomplished by analyzing upstream regulators in all our datasets. Thereby, we determined how different brain
infectome components were interrelated. Cluster protein-protein interaction analysis revealed additional, functional correlates. Associations between the T. gondii brain infectome and other diseases that share these signature
interactions were determined using our empirical, primary data.
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Figure 1. Methodology and analyses for understanding interaction of Toxoplasma gondii with human brain.
(a) Gene-environment-pathology paradigm. The Venn diagram shows model of pathogenesis with confluence of
permissive host and parasite genetics, and exposure. (b) Flow diagram of empirical genetic and biomarker data from
NCCCTS, transcriptomics and proteomics. (c) Structure of the manuscript. This includes original empiric data,
methods for analyses, and contributions of components to analyses in each figure. *Empiric but not from NCCCTS
cohort; **Cell culture, IFA, microarray gene expression, mRNAseq, miRseq, quantitative proteomics, miR qPCR.
d. Reconstruction and deconvolution analyses. Reconstruction is the discovery, integration and systems analysis
of interrelatedness of four areas of primary, original data: genetics, transcriptomics and proteomics of infected
cells and circulating serum biomarkers in ill persons. Deconvolution refers to the systems analysis that examines
upstream regulatory genes, protein-protein cluster interactions and diseases with which biosignature pathways
associate. These are the topics of the current work and are elaborated on throughout this manuscript. Image of
family reproduced with their permission and also from “The Billion Brain Parasite”, Science Life (Easton, 2014).
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Results

Reconstruction and deconvolution of Toxoplasma gondii brain infection. Reconstruction
1. Susceptibility genes expressed in human brain provide insight into signature pathways of T. gondii in human
brain. Our unique NCCCTS cohort of persons with congenital toxoplasmosis and their families have been carefully characterized longitudinally13, 40–44 (Fig. 1). Ongoing evaluations of this cohort contributes to the first phase
of our present analyses as shown in the flow diagram in Fig. 1a. Figure 1b presents an outline of the work in this
study including how the genetic and cohort analyses form a basis for the work. Figure 1c shows that these cohort
and genetics analyses are integrated with other aspects of the current work in a model. Our NCCCTS cohort
is the source of previously published analyses11–39 which earlier provided a powerful tool to identify genes and
pathways causing susceptibility to toxoplasmosis (Table 111–39, Figs 1 and 2). These susceptibility genes identified
earlier are considered along with susceptibility genes newly identified herein. All these genes are part of our further analyses in this present manuscript. In our earlier work, the human susceptibility alleles of candidate genes
identified for those in the NCCCTS were HLA Class I and II genes, ERAP 1, COL2A1, ABCA4, P2RX7, ALOX12,
NALP1, IRAK4 (Table 1). Some of these gene/susceptibility associations were further confirmed using samples
from the European Cohort study (EMSCOT)12, 14. One association, with NOD239, was present in a Brazilian
Cohort with eye disease, but not found in the NCCCTS. Characterization of mechanisms associated with ERAP1
were extended in studies of cross presentation of antigen45. Peptides interacting with MHC Class I genes of greater
than usual octamer/nonamer lengths45 also were identified, suggesting that T. gondii subverts its host’s immune
defenses with aberrant splicing of polypeptides46. These genetic data and their analysis are summarized in Table 1
and Fig. 2a and b. The newly identified genes or phenotypes identified herein are labeled “AM” or “OD” in Table 1.
These susceptibility alleles indicated that the candidate genes were playing a role in susceptibility to toxoplasmosis
and some have been studied for corresponding phenotypes to explain that susceptibility. The previously described
genes are combined with newly identified genes for the analyses herein.
In a preliminary, initial network reconstruction analysis performed with Ingenuity Pathway (IPA), we noted
that NFκB and TGFβ were central nodes in the network (McLeod, R, Lorenzi H, et al., JCVI White Paper; http://
gcid.jcvi.org/docs/Toxoplasma_gondii_06152012.pdf). Therefore, they became predicted candidate susceptibility
genes. Using Transmission Disequilibrium Testing (TDT) with DNA from the families in the NCCCTS, we further confirmed herein that NFkB and TGFβ were actually empirically confirmed human toxoplasmosis susceptibility genes (Table 1, Fig. 2b, Supplement B: Table S1). Our sequential analysis of other candidate susceptibility
loci presented herein, found that TREX1, TIRAP MAL, FOXQ, and TLR9 also had allelic variants significantly
associated with susceptibility to congenital toxoplasmosis in the NCCCTS (p < 0.05) (Table 1).
It is noteworthy that all these identified, critical genes are expressed in the human brain, as shown in red coloration in Fig. 2a. Specifically, expression analysis using the Allen Human Brain Atlas (ABA) followed by 3-D Brain
Explorer 2 software analysis revealed that all 17 candidate susceptibility genes are expressed in the human brain47.
Z-scores of RNA expression of 6 human brains in the ABA database demonstrated localization and increased or
decreased expression of these genes in these human brains (Fig. 2a) in the hippocampus, choroid plexus, and
globus pallidus.
Our genetic analyses provided a foundation for systems analysis of congenital toxoplasmosis as it affects the
human brain (Figs 2b, S2). Upstream regulators of all these genes also were identified: a network of our susceptibility genes and upstream regulators was constructed with IPA (p-value of overlap <5 × 10−3; Fig. 2b) to identify
critical connecting nodes (genes). IFNϒ, TLR4, TAP 1, JUN, MYC, TNFR were identified as upstream regulators,
among others (Fig. 2b). Among 112 upstream regulators of these genes (Fig. 2b), 96 mediate both cellular growth
and proliferation (p = 5.22 × 10−35) and cell death and survival (p = 3.26 × 10−37; Supplement B: Table S2).
Reconstruction 2: T. gondii modulates human brain stem cell transcriptomes and proteomes. Human primary
neural stem/progenitor cells (stem/progenitor, stem or progenitor can be used to describe them because the
degree of stemness of the two primary cell lines studied here is still not certain, even though both are highly
potent clonogenic cells that should have many common phenotypic characteristics since both lines were isolated and expanded from human hippocampus following temporal lobectomy for intractable epilepsy48, 49) were
selected for these studies because they are multipotent cells central to neurodevelopment and neuroplasticity. To
determine whether T. gondii can perturb human neural pathways that contribute to the generation, differentiation and survival of normal circuitry components, including cell death and protein misfolding and degradation,
we characterized the host cell functional response, at transcript and protein level, of these two primary human
temporal-lobe neural stem cell lines (NSC, Table 2) generated in two different laboratories. One of these cell lines,
we named L-NSC, is a partially differentiated neuronal stem/progenitor cell48. L-NSC (Fig. 3a left panel, Table S3)
is known to immunostain with antibodies to well-established neural stem cell/astrocytic and neuronal progenitor markers Nestin and glial fibrillary acidic protein, “GFAP” (data not shown here). L-NSC are shown here to
also be immunoreactive for NFκB which is involved in DNA transcription, cell survival, cytokine and growth
factor production, and Stat3 which is also involved in cell growth and survival. These cells, as well as the second
neuronal stem cell line studied named S-NSC, are able to take up the thymidine analogue bromodeoxyurdine,
“BrdU”, indicating their ability to replicate and expand impressively in vitro. The second NSC studied was initially isolated and characterized by Steindler et al.49 (S-NSC, Supplement B: Table S3). These genetically distinct,
primary human temporal-lobe neural stem/progenitor cells also express the neural stem cell markers Nestin and
GFAP and can be differentiated into neurons and glia both in vitro and following intracerebral transplantation49
(Fig. 3a right panel, showing phase microscopic and immunostaining for astroglial stem/progenitor cell markers
of the human neural progenitor cell line). S-NSC allowed us to study a second biologically distinct human brain
NSC to compare with our L-NSC. Because of distinguishable isolation and in vitro growth conditions between the
two laboratories, along with known interclonal heterogeneity that has previously been shown for clonogenic NSC
lines even generated from the same human hippocampal specimen50, it is always anticipated that profiling of the
ScieNtific REPOrTS | 7:11496 | DOI:10.1038/s41598-017-10675-6
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Gene

SNP (Allele)

HLA Class II

COL2A1

ABCA4

P2RX7

P Value

DQ3

<0.02

DQ1

<0.0005

rs6823 (G)

<0.03 (brain)

rs2276455 (A)

<0.03

rs2276455 (G)*

<0.0005

rs1635544 (C)

<0.03

rs2070739 (T)

<0.02

rs2276454 (A)

<0.007

rs3803183 (T)

<0.02

rs3803183 (T)*

<0.003

rs952499 (C)

<0.03

rs952499 (T)*

<0.005

rs2297633 (G)*

<0.0003

rs1761375 (G)*

<0.0001

rs3112831 (C)*

<0.02

rs1621388(C1772T)

<0.021

rs1718119(T1068C)

<0.015

Reason Candidate
Gene

B

<0.01

Hydrocephalous in children (DQ3), Fewer
cysts in HLA transgenic mice (DQ1)

11

ED

EMSCOT replicates, imprinted, brain and
eye disease

12, 13

HC

EMSCOT replicates, imprinted, localized in
human brain

12, 13, HC

OI

EMSCOT replicates for differing alleles; ATP
mediated cell death, cytokine signaling, proinflammation

14, 15, OD

MD

Genotype association and phenotypes
humans and mice. PBMC from cohort.
Peptides for HLA A2, A11, B7 confer
protection

16–22, OD

LfL

Genotype association and phenotypes
humans and mice

16, OD

IOID

Genotype; phenotype, cell death,
inflammation

23

MD TRNG

Genotype (MD region; human); phenotype,
cell death, inflammation; MD

24–30

MD TRNG

Genotype and phenotype, cell death
proinflammation

TLRs

Brazil and Poland replicates; phenotype,
ligand
Genotype; Phenotype TLR signaling and
cytokines

C
ERAP1
IRAK4

NALP1

ALOX12

rs149173(T/C)

<0.0077

rs17481856(C/T)

0.0253

rs1461567

<0.023

rs4251513

<0.045

rs8081261

<0.002

rs11652907

<0.02

rs9902174

<0.04

rs6502997

<0.0003

rs312462 (C)

<0.03

rs6502998 (C)

<0.03

rs434473

<0.04

Reference/
Supporting Data

MD

A
HLA Class I

Replicate/Proof of Principle/Phenotype

31

32

rs574386 (T1905C)

<0.008

rs352140 (C)

<0.0001

TIRAP

rs8177374(S180L)

<0.006

IOID

FOXQ1

rs920209

<0.02

HC

Note NK cells mice

33, OD
34, 35, OD or
AM

TLR9

AM
AM

TREX1

rs 2242150(A/T)

0.02

SPD

Related clinical & Type 1 IFN phenotype,
LFL

NFκβ1

rs997476(C/A)

<0.02

CtoPiEA

Phenotype, nuclear localization, signaling
pathway

36, OD

TGFβ1

rs10417924 (G
overtranscribed)

0.016

CtoPiEA, MD

Phenotype transcriptomics, GRA1

37, 38

NOD2 (Brazil)

rs3135499 (C/A)†

<0.04

LfL Brazil

Eye Disease, IL17, CD4+

39

Table 1. Genes with Susceptibility/Resistance Alleles Defined with National Collaborative Toxoplasmosis
Study and EMSCOT Cohorts. Abbreviations: Reason for selection of gene to test sequentially as single
candidate gene in NCCCTS (1981–2016): MD, Murine model data; ED, Eye disease in humans caused
by mutation of this gene; HC, Hydrocephalous caused in humans by gene mutation and adult macular
degeneration associated with allelic variants; OI, Implicated alleles for other infections; LfL, Logical to test
from literature and other findings, for example MHC Class I presentation of antigen for ERAP1; IOID, Gene
in other diseases in the literature; MD TRNG, Toxo 1 region, not gene initially in humans based on rat Toxo
1 region; TLRs, Testing TLR genes now replicated by other cohorts and proven to be important in mice;
SPD, similar pattern of brain disease as AG brain disease due to DNA ligase mutations; CtoPIEA, Central to
genetic pathway identified with original analysis led to TDT analysis herein. Note: LfL Brazil, Minas Gerais,
did not replicate in US full cohort; no *, significant in NCCCTS not EMSCOT;* significant in EMSCOT
cohort not NCCCTS. P values are nominal. Supporting Data [SD]: References (#) with narrative summary
of findings and gene function for published work or in preparation (AM) or original data in this manuscript
(OD) in Fig. 1 or online supplement.
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Figure 2. Susceptibility genetics. (a) Expression and localization in human brain utilizing Allen Brain Atlas
of genes with alleles conferring susceptibility to congenital toxoplasmosis in National Collaborative Chicago
Based Congenital Toxoplasmosis Study (NCCCTS). Transcript expression is visualized for brain of the youngest
donor (H0351.2001, 24 years, male, African-American). Z-score of microarray data ranges between −3 and +3
to quantify the lowest to highest expression (see Supplement B: Table S2). (b) Ingenuity Pathway Analysis (IPA)
of NCCCTS susceptibility genes and upstream regulators. Cut off of p value at 5 × 10−3 generated a network of
117 predicted upstream regulators (see Supplement B: Table 2). Upstream regulators and susceptibility genes
are consolidated/bundled and graphically mapped. Susceptibility genes are manually relocated in IPA graphic to
show connectivity to upstream regulators. Note NFκB and TGFβ are central nodes that are visual.
two lines under any condition should reveal similar but not identical molecular signatures. For both cell types,
and the differentiated form of S-NSC (S-NDC), the transcriptional responses were characterized using differing
in vitro culture conditions (Table 2), with and without T. gondii infection. These studies were complemented
with transcriptomics analyses on a human monocytic cell line (MonoMac6, MM6, Supplement B: Table S13)25 to
reflect inflammatory cells that enter the human brain. All four types of cells were infected with parasite isolates
representative of the three clonal types of T. gondii that predominate in the U.S. and Europe (Types I, II and III).
To characterize the transcriptional response of each of the four human cell types to the infection of genetically
ScieNtific REPOrTS | 7:11496 | DOI:10.1038/s41598-017-10675-6
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Growth Factors (ng/ml)

Days to
Differentiation

Cell

Medium

Serum

EGF

bFGF

NGF

Other

Markers

NPC-LS*

DMEM/F12

0,5, or 10%
FCS

20

20

0

N2 supplement/ 1 μg/
ml laminin

Nestin, GFAP,
Neur

N/A

S-NSC

DMEM/F12

5% FCS

40

40

0

N2 supplement/
Bovine Pituitary
Extract

Not Present

0

S-NSC-LNS

DMEM/F12

0

0

0

25

c-AMP 05 um IBMX
0.5 uM

Rare: Nestin,
GFAP, Neur

14

S-NDC

DMEM/F12

0

0

0

25

c-AMP 05 mM IBMX
0.5 mM

Nestin, GFAP,
Neur

7

Table 2. Neuronal cells, culture conditions, and markers. *Called L-NSC.
diverse parasite strains, we performed differential gene expression analyses of both protein-coding (L-NSC,
S-NSC, S-NDC and MM6) and miRNA-coding (S-NSC, S-NDC and MM6) genes for each infected culture condition compared to its respective uninfected control. Figures 3 and 4 summarize results of RNA profiling and
analysis of the T. gondii RNA brain infectome for L-NSC, S-NSC, S-NDC and MM6 cells. Significant modulations
(>1.5 log fold change of infected versus uninfected cells) were evident at 18 hours post infection with Type I, II
and III T. gondii tachyzoites. The bar on the heat map for L-NSC is the RMA normalized intensity.
The relatedness of results from all four types of host cells and identification of the signature pathways that the
parasites modulate were analyzed by heat maps (Fig. 3) and gene set enrichment analysis using Gene Ontologies
(GO) and KEGG pathways knowledgebase (Fig. 3c, Supplement B: Tables S16 and S17). This comparison revealed
critical similarities and differences between different cell types and culture conditions. Some of these modulations were unique to different parasite strains and cell types. The heat maps also showed effect of host cell type in
Fig. 3b. The overlap and differences of expression are shown in Fig. 4a–e. In MM6, modulation of P53 signaling,
JAK-STAT signaling, programmed cell death, arachidonic acid metabolism, response to hypoxia were noteworthy
(red arrows in Fig. 3c, right panels). Effects on translational elongation, apoptosis, cell cycle, vesicle mediated
transport, ribosomes, amino acid metabolism, TGFβ signaling, p53 signaling, MAP kinases, circadian rhythm,
and cell cycle were some especially noteworthy in GO and KEGG pathways for S-NSC (red arrows in Fig. 3c). In
infected L-NSC, transcriptomes also showed that parasites modulate pathways of sensory perception of smell,
mitochondrial organization, protein modification by small protein conjugation, cognition, neurologic system
processes, neddylation, oxidative phosphorylation, G protein coupled receptor protein signaling, androgen and
estrogen metabolism, ribosomes, translational elongation, and particularly noteworthy, pathways of Parkinson’s,
Alzheimer’s and Huntington’s diseases (Fig. 3c). Specific genes in the L-NSC pathway analysis are shown in
Tables 16 (GO) and 17 (KEGG). Specific T.gondii susceptibility genes that also contribute to these pathways and
functions are in Table 1 and Supplement B: Tables S16 and S17. This transcriptomic analysis also served as a basis
for an analysis of upstream regulatory genes shown later.
It was notable that a significant number of pathways modulated by T. gondii in human NSC reflect immunologic mechanisms. This made the comparison of the transcriptomic differences between NSC and this monocytic
cell line at a stage before maturation (Mono-Mac 6) of interest. This allowed us to identify the distinct and common modification in each of these cell types. We also compared their messenger RNAs (mRNA) and micro-RNAs
(miRNA) with NSC that are stimulated (NDC) by Nerve Growth Factors for 7 days. Human MM6, NSC, and
NDC each were infected with Type I (GT1), or Type II (PRU or ME49) or Type III (VEG) parasites for 18 hours.
The differential transcriptional responses are significantly different between NSC and NDC, as well as when
compared to MM6 (Fig. 4). Direct comparison of the transcriptome profiles also demonstrated that differences in
protein and miRNA coding gene expression were mostly influenced by host cell types rather than parasite type, in
particular for MM6 and S-NSC cells (Fig. 4a–e). This comparison further demonstrated the substantial numbers
of human genes modulated during parasite infection that were not shared among the different host cell types
assessed and the NDCs in different culture conditions. This comparison underscores immune-type responses
in human neural stem cells but also that they are not the only pathways perturbed. In addition, we identified
some interesting parasite-specific pathways perturbations. Notably, pathways for Alzheimer’s, Parkinson’s, and
Huntington’s diseases have the same genes being affected by infection modifying oxidative phosphorylation that
were prominently modulated for L-NSC, but only when infected by Type II (ME49) parasites. Baseline levels also
differed between cell types (Fig. S1).
Significant changes in gene expression were also evident by miR-seq for MM6, S-NSC and S-NDC cells at
18 hours post-infection (Figs 3 and 4 and Supplement B: Tables S11 and S12). These included mirs 139, 132, 29a,
107, 218, 143, 155, 199a, 21, 16, 181b-1.
L-NSC and S-NSC infections with Type I, II, III parasites were also studied using iTRAQ quantitative proteomics (Fig. 5). Differential protein expression analysis of L-NSC cells identified only three primary candidate proteins with significant fold change increases in infected cells. These proteins were Ataxin 2-like protein
(ATXN2L); Fragile X-related protein 1 (FXR1); and Niemann-Pick-like protein (NPC2) (Fig. 5a, Supplement B:
Table S4). An IPA later showed how these three proteins were linked to transcriptomic infectomes and identified
congenital toxoplasmosis susceptibility genes (Figs 6, 7). These proteomics and transcriptomics (Figs 3–5) defined
empirically, responses of human L-NSC to infection with T. gondii.
Quantitative proteomics of S-NSC identified 20 proteins that presented at least a significant (p < 0.05)
1.5-fold change in abundance in response to T. gondii infection compared to uninfected controls (Supplement
B Table S15). Interestingly, this includes a number of proteins that participate in the regulation of the immune
ScieNtific REPOrTS | 7:11496 | DOI:10.1038/s41598-017-10675-6
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Figure 3. Transcriptomics and their Analyses. (a) Immunostaining of L-NSC and S-NSC cell lines. Left panel
in a shows L-NSC cells stained for nestin (green) and Tuj1 (red) (upper row, 20X), Stat 3 (middle row, red) and
NFκB (lower row, green), nuclear counterstain blue, DAPI (40X). The right side of the left panel in a shows
L-NSC cells immunostained for the cell proliferation marker bromodeoxyuridine, BrdU(upper panel), and
propidium, PI (lower panel), nuclear counterstained, DAPI blue (40X). A, right panel, phase microscopic image
of S-NSC cells in culture; top panel shows DAPI counterstaining of a nucleus from a cell immunopositive for
the cytoskeletal and neural stem/progenitor cell marker proteins nestin (red) and GFAP (green). The panel
below shows a single double labeled S-NSC cells double labeled for nestin and GFAP, merged image. The S-NSC
double labeled cell interestingly possesses the same morphology and immunostaining pattern of cytoskeletal
elements as originally shown in immunocompromised mouse xenografts of the original parental line following
intracerebral transplantation and their homing to neurogenic regions (Fig. 3f in Walton et al. Development,
200649). (b) Heat maps showing differentially expressed protein coding and miRNA genes. Left panel, L-NSC
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microarray gene expression data. Upregulated and downregulated genes in infected cells are shown in red
and blue respectively. Middle panel, S-NSC differentially expressed protein-coding genes. Red and green
represent genes over- or under-expressed in infected cells respectively. Right panel, microRNA genes over(red) and under-expressed (green) in infected S-NSC. (c) Functional enrichment analysis of transcriptomics
datasets focused on KEGG pathways and GO Biological Processes. Left panels, enrichment analysis on L-NSC
transcriptomes; right panels, enrichment analysis on MM6 cells and Steindler’s NSC and NDC cells. Red
arrows indicate interesting pathways. DEGs, GO Biological Processes enriched with DAVID software v6.7. GO
Biological Processes, p-value < 0.01, number of genes associated with certain GO term >5. (j) KEGG pathway
enrichment analysis. Identified DEGs, KEGG pathways enriched with DAVID software v6.7. KEGG pathways,
p-value < 0.05. For L-NSC GO and KEGG analysis show neddylation, pathways of Alzheimer’s, Parkinson’s and
Huntington’s diseases. For S-NSC there are a variety of interesting pathways marked by red arrows, as in MM6
and NDCs as well involving ribosomes, p53 signaling, cell cycle, TGFβ, purine metabolism, NOD receptor
signaling, MAPK signaling, vesicle mediated transport among others. Nominal p values were utilized for KEGG
and GO analyses; p-values for pathways that were robust to Benjamini Hochberg correction also are shown
in Supplement B: Table S16, 17. Comparison of the nominal and corrected p values indicate the most robust
pathways.

response, cell proliferation and cancer, protein ubiquitination, and neurodevelopmental disorders. Modulated
proteins of interest included WDF41, PPP4C, USP8, UBE3A, ECF1A2 (Fig. 5b, Supplement B: Table S6).
Contrary to L-NSC, S-NSC cells did not show any significant change in the level of ATXN2L, FXR1 or NPC2
proteins. S-NSC proteomics also revealed that some of the pathways whose gene expression was perturbed during T. gondii infection (Fig. 5b,c) were also modulated at the protein level. (Please see response to wounding and
regulation of TOR-signaling pathway in Fig. 5c, right panel; Supplement B Table S15). In summary, S-NSC proteomics, pathway and GO enrichment analyses showed signaling pathways impacting on cell death, TOR, protein
transport/localization and RNA splicing. Oxidation reduction, vesicle mediated transport, iron homeostasis and
glucose metabolism were also influenced, some differentially by parasite type (Fig. 5c). Consistent with these
enrichment results, prediction of alternative spliced isoforms in our transcriptomics datasets identified a number
of candidate genes predicted51 to be differentially spliced during parasite infections (Supplement B: Table S14).
Reconstruction 3: Serologic biomarkers reflect infection and neuron damage. Human serum biomarkers of three
ill congenitally infected children from the NCCCTS (A1,B1,C1 in Fig. 6a–c) reflected T. gondii infection and neuronal damage when compared against age, sex, and demographically matched controls (A2,B2,C2) in Fig. 6a–c.
Each of the three ill children had new myoclonic-“infantile” spasms, or hypsarrhythmic seizures (Fig. 6a). For
two of them, A1 and B1, this was associated with a rise in or high T. gondii specific IgG antibody titers. IgG was
not measured for the third ill child, C1. Child C1, who decades earlier, was recognized to have congenital toxoplasmosis and later developed hypsarrhythmic seizures decades. A1 and B1, diagnosed more recently, had T2
weighted abnormalities in brain MRIs. C1, with this clinical problem was cared for prior to the development of
regular clinical use of MRIs. The findings in the ill children were similar to active inflammatory and parasitic
caused brain disease such as epilepsy and motor abnormalities, and the T2 weighted abnormalities, seen in a
murine model4. These similarities prompted us to look for serum biomarkers for active brain damage in the
setting of chronic congenital toxoplasmosis. In the murine model studies, T2 weighted abnormalities in MRIs
correlated with chronic and active inflammatory brain pathology characterized with light and electron microscopy studies. To identify potential serologic biomarker signatures associated with the aforementioned neurologic
manifestations of toxoplasmosis, we assessed a panel of 700 miRNA transcripts by RT-qPCR and performed
proteomics on serum samples obtained at the time of appearance of this new illness for the ill children and at the
same age for the control children. These miRNA panels had shown biomarkers associated with neurodegenerative diseases52. Serum miRNA profiling detected four miRNA transcripts with more than 2–fold increases in the
sera of at least one of the three infected children compared to their paired healthy controls (Fig. 6b and c). These
include mirs 17, 186, 19a, 124 all encoded by miR 17-92 family cluster. Proteins that increased included clusterin
(CLU), serum amyloid P component (APCS), and Oxytocin (OXT) (Fig. 6d,e). N-acetylmuramoyl-L alanine
amidase (PGLYRP2) and Apolipoprotein A1 (APOA1) decreased (Fig. 6).
To elucidate potential relationships between candidate serologic biomarkers, our susceptibility genes and their
upstream regulatory pathways, and toxoplasmosis, we performed IPA network analysis (Fig. 6e). This analysis
revealed that biomarkers from sera of some cohort members, and susceptibility genes and their upstream regulators are interconnected. IPA analysis was performed to elucidate potential relationships between candidate
serologic proteins and toxoplasmosis susceptibility genes, such as upstream regulators (Fig. 6e, Supplement B:
Tables S2 and 7). Comparison of top-scored IPA canonical analysis showed that atherosclerosis signaling may
relate to interactions between CLU and proteins encoded by congenital toxoplasmosis susceptibility genes
(TGFβ1, COL2A1, ALOX12, NFκB1). Atherosclerosis was also facilitated by association with other genes in RNA
infectomes of L-NSC (2 genes) and S-NSC (10 genes). Disease and function analysis indicated that additive effect
of congenital toxoplasmosis biomarkers activate mechanisms of immune cells and neurons, synthesis of prostaglandins and a dominant shift to cancer potentiation.
Deconvolution 1. IPA analyses reveal upstream regulators. First using only the findings from L-NSC, the four primary original data sets were combined as a total brain infectome. The sum is 1,678 human genes that were assembled from Type I (347 genes), Type II (1,225 genes), and Type III (801 genes) parasitic infections (Supplement
Table S7). We determined by IPA analysis the top 25 upstream regulators and created an ‘Orbital’ design to
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Figure 4. Comparative analysis of MM6, S-NSC and S-NDC transcriptomics profiles by cell type and parasite
strains. (a) Number of protein-coding genes (DEGs, left panel) and miRs (DEmiRs, right panel) differentially
expressed between infected and uninfected conditions. This is with a false discovery rate ≤0.01 and absolute
log2-fold-change ≥1. (b–e). Number of shared over- or under-expressed protein-coding genes (b and c) or miR
genes (d and e) grouped by host cell type (b and d) or parasite type (c and e). Both cell type and parasite strain
drive differential response, with a predominant effect from the host cell type. Nominal p values were utilized
for KEGG and GO analyses. Pathways that were robust to Benjamini Hochberg correction also are shown in
Supplement B: Tables S16, 17.
visualize the connections between 5 “layers” (Fig. 7). Each data set represented a ‘layer” visually: (I) Human
susceptibility genes; (II) Human brain serum biomarkers; (III) Differential proteins in neuronal progenitor cell
(L-NSC); (IV) Differential RNAs in neuronal progenitor cells (L-NSC, S-NSC); and (V) Predicted Upstream
Regulators.
The top-ranked 25 upstream regulators were modulators of important pathways of the neural, immune and
endocrine systems, including cytokines (CSF2, IFNA2, IFNG, IL1B, TNF), growth factors (HGF, TGFβ1, VEGF),
immunological transmembrane receptors (TLR4, TREM1), transcriptional regulators (CTNNB1, EP300, RB1,
SMARCA4, SP1, STAT3, TP53, TP73) and hormone regulators (ESR1, Cg complex) (Fig. 7). Predicted upstream
regulators connected the proteins detected in infected NSC in layer III such as FXR1 to oncogene TP73 and NPC2
to SMARCA4. The brain biomarker (called “layer II”) also showed connectivity, e.g., hormone oxytocin detected
in the infected brain serum associated with immunological upstream regulators TREM1 and IL6, whereas peptidoglycan recognition PGLYRP2 connected with oncogene TP53 regulatory networks. Portions of analyses are
shown in Supplement B: Table S7.
The transcriptome and proteome of the S-NSC were not included in this initial analysis. Therefore, we performed an upstream regulatory gene analysis (Fig. 8) which shows separate and overlapping upstream regulatory
genes for our two experimental types of primary neuronal stem cells. This analysis includes all the genes identified by both transcriptomics and proteomics from L-NSC and S-NSC. The upstream regulators, had been shown
earlier to be related to the susceptibility genes and circulating biomarkers in the ill children (Figs 2b, 7a,b). These
are apparent and those upstream regulators that are common to both types of cells are seen in the Venn diagram
and Table in Fig. 8. That the different cell types also have distinct upstream regulators is also notable in the Venn
diagram (Fig. 8). The colors in Fig. 8 indicate which analysis and type of cells contribute which components to this
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Figure 5. Proteomics and their Analyses. a-b. Proteins differentially expressed during parasite infection of
L-NSC (a) or S-NSC (b). ATXN2L, Ataxin 2-like; NSC2, Niemann-Pick disease, type C2; FXR1, Fragile X
Mental Retardation Autosomal Homolog 1; WDFY1, WD Repeat And FYVE Domain Containing 1; UBE3A,
Ubiquitin Protein Ligase E3A; USP8, Ubiquitin Specific Peptidase 8; PPP4C, Protein Phosphatase 4 Catalytic
Subunit). (c) Left panel, number of differentially expressed proteins (DEPs) in S-NSC infected with T. gondii
types I, II and III; right panel, GO Biological Processes significantly overrepresented (p-value < 0.01) in the set
of 3,359 proteins differentially expressed in infected S-NSC compared with their respective uninfected controls
(>2-fold change and false discovery rate <0.1). Nominal p-values were utilized for KEGG and GO analyses.
Pathways that were robust to Benjamini Hochberg correction also are shown in Supplement B: Table S15.

upstream regulator analysis. Some of the genes critical in a variety of chronic complex disease pathways, immune
response, and neurodegeneration are seen in this analysis. A few examples of key upstream regulators and their
functions are NFkB, VEGF, MYC, EGFR, FGF, TGFβ, PI3K/AKT/PTEN, ERK, PI3K, FoxOs, GM-CSF, and FGRR1.
Additional details of and from this analysis is provided in the methods.
Deconvolution 2. Cluster protein interactions reveal critical mechanisms of pathogenesis. Our second deconvolution approach used network analyses of protein-protein interactions on L-NSC total infectome (Fig. 9). Whereas
IPA is designed to annotate pathways and networks, STRING database and web tool provide an analysis that
detects protein-protein interactions53. Due to the limit of 30,000 interactions in STRING graphical tool, clustering deconvolution was only completed for L-NSC brain infectome (susceptible genes + biomarkers + L-NSC
RNA + L-NSC proteins). We analyzed separate and combined data sets of Type I, II, and III infections.
T. gondii brain infection was deconvoluted into six simplified functional clusters (Fig. 9, Supplement B:
Table S6). Four clusters (1a, 1b, 2, 3) pivoted around a central node defined by NEDD8 (neural precursor cell
expressed, developmentally down-regulated 8). This central node was potentially involved in hijacking cellular
proliferation and cell death by either protein neddylation or sumoylation. The largest Cluster 1a was predominantly associated with cellular movement and migration that utilizes mechanisms described for immune and
endocrine signaling. Cluster 1b appeared to be more specific for leukocyte migration and may involve parasitism
of brain’s lipid metabolism. Cluster 2 also mediated cellular proliferation but appears to be more specific to the
role of ubiquitin-mediated protein degradation in cell cycle control. Cluster 3 pinpointed the parasite’s hijacking
of protein synthesis to regulate the host cell cycle. Cluster 4 revealed the parasite’s capacity to modulate the brain’s
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Figure 6. Serum biomarkers from boys with active brain disease due to T. gondii reflect infection and
neurodegeneration. (a) Tabular clinical summary: Three pairs of children, matched demographically; one in
each pair had severe disease and the other mild or no manifestations. One pair dizygotic, discordant twins.
Each ill child had new myoclonic or hypsarrythmic seizures. Two children had T2 weighted abnormalities on
brain MRIs similar to active inflammatory and parasitic disease in murine model4. (b–d) Protein and miRNA
serum biomarkers: Panel of protein and miRNA profiling performed on serum obtained at time of new illness.
Changes in serum miRNA concentration between each infected child and corresponding control is expressed
as the difference in RT-qPCR Ct-values for miR-124 (b) and miR-17, miR-19a and miR-18b (c). Abundance of
peptides measured. In Fig. 6b and c, these data are extracted directly from the qPCR panel for miRNA profiling.
(d) Left panel, schematic representation of the genes targeted and pathways modulated by miRNA clusters
17–92; right panel, peptide abundances from the 10 most intense peptide ions detected by proteomics in the
three children pairs. Peptides with higher or lower abundance in ill children compared to healthy controls
are depicted above or below the dashed line respectively. (e) Bundling of upstream regulators predicted from
susceptibility genes (red box) and brain biomarkers (blue box). See Supplement 2 for IPA analysis of upstream
regulators with p-value <5 × 10–3. Circulating biomarkers detected in the T. gondii infected brain are clusterin
(CLU), oxytocin/neurophysin I prepropeptide (OXT), peptidoglycan recognition protein 2 (PGLYRP2), and
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microRNAs (miR214, miR-17, miR-18b, miR-19a) (Fig. 4B, Supplement B: Table S7). These specific miRNAs
were not annotated in the IPA database, so the analysis focuses on the 3 protein biomarkers. PGLYRP2 is a
hydrolase that recognizes and digests bacterial active peptidoglycan into biologically inactive fragments that
triggers innate immune responses to intracellular pathogens. Clusterin/Apolipoprotein J is a secreted chaperone
which is proposed to be a biosensor of oxidative injury. The ‘love/bonding hormone’ Oxytocin is a posterior
pituitary hormone that is synthesized in the hypothalamus. OXT hormonal activity influences cognition,
tolerance, adaptation and complex sexual and maternal behavior, as well as the regulation of water excretion
and cardiovascular functions. Presence of markers of neurodegeneration and inflammation include Clusterin,
PGLYRP2, and Oxytocin in ill children compared with their healthy controls.

ATP production by mitochondrial oxidative phosphorylation. Cluster 5 suggested the alteration of olfactory
response due to brain parasitism. Nedd8 is a critical, key central node (Fig. 9).
Deconvolution 3. T. gondii modulates proteins involved in neurodegeneration, epilepsy, motor diseases and malignancy. The third deconvolution approach was to predict global correlation between T. gondii infection and common neurological diseases using IPA disease and function tools. Only top-ranked canonical, diseases-functions
and network pathways were included, with complete tabulations in Fig. 10. We discovered correlations with four
major groups of epilepsy (81 genes), neurodegeneration (101 genes), motor disease (162 genes), and brain malignancy (1,188 genes) (Fig. 10, Supplement B: S10A,B). We found only 1 association with a schizophrenia network
(p = 8.63E-12) of 19 genes.
IPA canonical analysis was performed to determine potential networks associating with diseases. Epilepsy
gene group indentified top-ranking signaling pathways that were associated with retinoic acid receptor (6 genes),
endothelin-1 (6 genes), Gq alpha protein (5 genes) and corticotropin releasing hormone (5 genes). Movement disorders mediated by the brain temporal lobe indicates signaling pathways mediated by G-Protein coupled receptor
(13 genes), cAMP (10 genes), transcriptional regulator 14-3-3 (7 genes), cytokine Endothelin-1 (8 genes), polypeptide hormone relaxin (9 genes) and corticotropin releasing hormone (8 genes). The neurodegenerative disease
gene network was potentially mediated by signaling pathways of adaptor protein 14-3-3 (7 genes), retinoic acid
receptor LXR/RXR (7 genes), tumor suppressor protein p53 (7 genes), cytokine IL-17A (5 genes) and glucocorticoid receptor (13 genes). The most significant disease correlation to total brain infectome was cancer in which
1,188 of 1,678 genes are associated with a wide range of cancers (Fig. 7e, Supplement B: Tables S8; 10A,B). The top
10 canonical pathways determined by IPA reveal important mechanisms that may potentiate cancer development
in the T. gondii-infected brain, such as Wnt/Ca + (14 genes) and inflammatory IL-17A (14 genes) pathways.

Selected phenotypes: T. gondii type I, II and III induce activation of the NFκB pathway in human
neuronal stem cells. Reconstruction and deconvolution of the T. gondii infected brain provides a substantial

number of biologically relevant mechanisms to investigate. A few selected phenotypes found in the informatics in
our human neuronal stem cells were selected for study. These studies provide empirical validation of the conclusions from bioinformatics analyses (Fig. 11). Pathways identified through systems analyses of genetics, transcriptomics, proteomics, and with circulating biomarkers from matched pairs of well and ill children suggested that
we might find empirically that these parasites would influence similar functional phenotypes in primary, human,
neuronal stem cells which have not been characterized with Types I, II, III isolates of this common brain pathogen
before. As downstream signaling molecules associated with an inflammatory process including NFκB and STAT3
had been identified in human neuronal stem cells (Fig. 2), we investigated whether Type I, II or III tachyzoites
would modulate host gene expression in NSC by determining whether there was modulation of the NFκB pathway by the parasite. We infected S-NSC with Type I, II or III tachyzoites for 24 hours and followed translocation of
NFκB p50 subunit and STAT 3 by immunofluorescence. As shown in Fig. 11, NFκB and STAT3 also were found in
human neuronal stem cells in this experiment (Fig. 11a). We found that Types I,II,III tachyzoites infection of cells
all affected nuclear localization of NFκB1 and STAT3 (Fig. 11a). Supplement B Table S9 shows canonical pathways
that include NFκB1 determined by IPA.
Another selected phenotype studied was neurotransmitters in T. gondii and NSC. T. gondii’s effect on pathways associated with neurotransmission has been reported by others including effects on tyrosine hydroxylase,
dopamine, and GABA receptors and distribution of GAD67 in murine brain infected by Type II but not Type III
tachyzoites. To investigate whether either tyrosine hydroxylase or dopamine, is expressed by T. gondii tachyzoites
when they are within NSC, we infected NSC with Type I, II, and III T. gondii tachyzoites for 24 hours. Type I, II,
and III T. gondii tachyzoites in NSC immunostain with antibodies to tyrosine hydroxylase and dopamine. Both
human host NSC dopamine and tyrosine hydroxylase were expressed in the parasite cytoplasm (Fig. 11b). We
find this dopamine-like immunostaining in Type I, II, and III tachyzoites (Fig. 11b,c). We have not confirmed the
exact nature and release of dopamine or other neurotransmitters including glutamate from these cells. A preliminary study (data not shown) also showed alterations of GABA and glutamate5 in S-NSC due to T. gondii infection
(Roberts, El Bisatti, Zhou, McLeod et al., unpublished studies in progress).

Intersecting susceptibilities and human diseases. Protein degradation and cell cycle are affected by T.

gondii. Our transcriptomic and proteomic analyses indicated that this parasite alters neddylation (NEDD8) and
ubiquitination which are key in clearing misfolded proteins, neuronal cell viability, and synaptic plasticity (Figs 3,
4, 9 and 11c). In the proteomics analyses, we also found that T. gondii modified alternative splicing (Fig. 5) and
that an rMATS analysis51 predicted transcripts that are alternatively spliced based on the S-NSC transcriptomics
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Figure 7. Deconvolution of total brain infectome reveals upstream regulatory pathways. a. Statistical
probability of 25 upstream regulators of total brain infectome (BI) with most significant p-values. The Total
Brain infectome included 1,678 genes from all datasets of genetics susceptibility, brain biomarkers, messenger
RNAs of L-NSC and S-NSC, and proteins of L-NSC. The BI is segregated into Type I, II and III infection
(see Supplement B: Table S7). IPA analysis of BI identified 1,640 upstream candidates (see Supplement B:
Table S7). ‘Target’ indicates the number of T. gondii-induced genes found in each upstream regulatory pathway.
TNF, TGFβ1, IFNG, TP53 and IL1β are the most dominant upstream regulators found in the T. gondii brain
infectome. (b) “Orbital” visualization. The 25 highest statistical valued upstream regulators (a) are added to
the brain infectome and graphically mapped by IPA. The relationships between the 5 reconstruction layers are
visualized in the “orbital diagram”. Specific genes are manually repositioned in each empirical ‘layer’ drawn to
‘orbit’ the core gene datasets. Upstream regulatory network (V) connects RNA (IV) and Protein (III) of human
NSCs, brain biomarkers (II), and NCCCTS Susceptibility genes (I). Since the IPA drawing program is limited
to 30,000 interactions lower than the cut-offs, ATXN2L was not found in this visual analysis. The total brain
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infectome is deconvolved into functional correlates by IPA Core Analysis. Canonical pathway annotation
reveals the predominant mechanism of IL-17 pathways in arthritis, psoriasis and allergy with related cell
types (macrophages, fibroblasts, endothelial cells, osteoblasts, osteoclasts, chondrocytes) playing a role in
the inflammation. Top pathways also include cardiogenesis, adipogenesis, hepatic stellate cell activation and
diapedesis of agranulocytes and granulocytes, molecular mechanisms of cancer accompanied with the signaling
of colorectal cancer metastasis. Wnt/Ca + pathway moderates axonal guidance signaling and other cell growth
and developmental pathways. The top scored canonical pathway shows also cell cycle control of chromosomal
replication as possibly a prevailing molecular mechanism. Supplement B:Table S8 describes the IPA analysis
of canonical pathways with functional mechanisms in neural stemness, neurodevelopment, neurobiology,
immunology, cancer, and cell cycle. Supplement B: Table S9 identifies pathways associated with the nuclear
factor NFkB.

data (Table S14) providing mechanisms whereby T. gondii may contribute to neurodegeneration, motor abnormalities, epilepsy, and malignancies (Figs 10, 11).

Discussion

The Venn diagram in Fig. 1a provides a model and an explanation that addresses why some persons might have
diseases to which T. gondii contributes, as suggested by our current analyses, and why other persons do not
have these diseases. We hypothesize that disease occurs in the presence of the relevant susceptibility genes, parasite genotype and other innate and environmental factors such as other infections, the microbiome, or stress
that influence immune responses, as shown in Fig. 1a. This reconstruction and deconvolution analysis presented
herein (Fig. 1b,c) and summarized schematically in Fig. 1d unveils a plethora of pathways known in neurologic,
immune and endocrine systems. These are likely to interact to cause neuropathologic diseases, depending on
genetics of infected individuals (Figs 1a, 2a). Focus on neuronal stem cells reveals pathologic mechanisms in neurodevelopment and neuroplasticity. For example, cytokines mediate migration and homing of immune cells that
serve parallel roles in spatial guidance of NSC in proper development and plasticity of human brain54. Cytokines
stimulating CD8+ T cells to control T. gondii in brain55 may disrupt normal brain development and plasticity. A
wide range of cytokines are evident in our data and interactome. Little is known about endocrine-type mechanisms in T. gondii infection56. This study provides a foundation to delineate endocrine influences and cross-talk
with immune and neural systems.
Certain of our observations of specific genes/molecules, interactions, and pathways apparent in our data
sets are particularly noteworthy: For example, in our genetics data (Table 1, Fig. 2), TREX1, TLR9, TIRAP Mal,
ALOX12, NALP1, NFκB, and TGFβ connect to pathogen sensing, changes in lipids, and cell death and replication
(Fig. 2). Characterization of phenotypes of our newly identified susceptibility genes is ongoing (Table 1): TREX1
was studied because of the similarity between the brain calcifications in congenital toxoplasmosis and in the
genetic Aicardi Goutiere’s disease that could be due to mutations in TREX1 (Naranjo-Galvis et al., manuscript in
preparation). TIRAP MAL (Hargrave et al., manuscript in preparation) (Table 1) was selected as a candidate gene
studied individually as a downstream signaling molecule from TLR2 and 4. FOXQ (Table 1) was next chosen as a
candidate gene because of a hydrocephalus association and subsequently has been shown to have a natural killer
(NK) cell mediated phenotype33. TLR9 was studied next as a candidate gene involved in recognition of small
fragments of DNA (Hargrave et al., manuscript in preparation). Noting this association for TLR9 in the NCCCTS
(Table 1), we also have replicated the importance of TLR9 in susceptibility to ocular toxoplasmosis in a cohort in
Brazil32.
The localization of these T. gondii susceptibility genes in human brain (Fig. 2a) also provides insights consistent with our clinical observations of toxoplasmosis in mice and humans who develop seizures originating in the
hippocampus-temporal lobe, impaired movement and hydrocephalus4, 41. Z-scores indicated that all of the 17
genes except COL2A are downregulated in the hippocampus. Memory, spatial navigation and control of attention occur in the hippocampus, which is also the dominant niche for neural stem cells. In the choroid plexus of
the lateral ventricle where cerebrospinal fluid is produced, eight susceptibility genes are up-regulated (ABCA4,
HLA-A, HLA-B, HLA-C, IRAK4, NFκB1, TGFβ1, TREX1), while five are down-modulated (ALOX12, COL2A1,
P2RX7, TIRAPMAL, TLR9). In the globus pallidus that regulates voluntary movement, the susceptibility genes,
other than ABCA4, ALOX12, COL2A1, NOD2, TIRAP, TLR9, are upregulated.
Upstream regulator analysis using IPA elucidates statistically significant upstream regulators including molecules which alter expression of downstream molecules. The systems analysis of upstream regulators of our susceptibility genes (Fig. 2b) underscores how this intracellular parasite influences the intricate balance between growth
and death of its host’s cells. Upstream regulatory networks associated with these genes by IPA (Fig. 2b) include
human genes that participate in inflammation, cell death, and cytokine signaling, as well as genetic, neurologic,
and retinal diseases.
The transcriptomics analyses demonstrate some effects that are similar and some that differ between cell types
(Figs 3 and 4). Possible explanations of the differences between cells include a number of variables including differences in the genetics of the host cells, fundamental differences in the cell types’ basal transcriptomics(Fig. S1),
differences in culture conditions including media, growth factors and timing when cells were studied, or different
responses to parasites. We also noted differences in responses when we studied another parasite called EGS which
grows as encysted bradyzoites in tissue culture in HFF, MM6, and S-NSCs. Pathways that are perturbed suggest
profound effects on host cells. These include for S-NSC: translational elongation, apoptosis, cell cycle, vesicle
mediated transport, ribosomes, amino acid metabolism, TGF-β signaling, p53 signaling, MAP kinases, circadian
rhythm, and cell cycle. For L-NSC: sensory perception of smell, mitochondrial organization, protein modification
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Figure 8. Upstream regulators targeting genes and proteins differentially expressed in S-NSC or L-NSC. (a)
Relationships of upstream regulators: 913 and 83 molecules were identified as upstream regulators of genes or
proteins differentially expressed in S-NSC and L-NSC, respectively (p-value ≤ 0.01). (b) Regulators in common.
Venn diagram shows that among the upstream regulators, 22 molecules are common between L-NSC and
S-NSC. (c) Gene regulatory network targeted by the 22 common upstream regulators.

by small protein conjugation, cognition, neurologic system processes, neddylation, oxidative phosphorylation,
G protein coupled receptor protein signaling, androgen and estrogen metabolism, ribosomes, translational elongation, and particularly noteworthy, pathways of Parkinson’s, Alzheimer’s and Huntington’s diseases. For MM6:
modulation of P53 signaling, JAK-STAT signaling, programed cell death, arachidonic acid metabolism, response
to hypoxia. Further, many of the perturbed miRNAs in the transcriptome have been associated with different
cancer types, neurodegenerative diseases and the NFkB activation pathway. For instance, both infected S-NSC
and S-NDC cells overexpressed mir-139, a microRNA that is overexpressed in the hippocampus of a mouse
model for Alzheimer’s Disease (AD) and associated with impaired hippocampus-dependent learning and memory57. In addition, S-NSC cells infected with T. gondii PRU tachyzoites had more than a two-fold reduction in
the expression of mir-29a and mir-107, found to be down-regulated in patients with AD58–61. mir-132, that is
under-regulated in post-mortem Huntington’s disease patients and in a mouse model for this disease62, showed a
~four-fold down-regulation in GT1 and PRU-infected S-NSC cells. Expression of other miRNA molecules, that
have been associated with the NFκB network and cancer, was also perturbed in S-NSC infected cells, such as mir218, mir-143, mir-155, mir-199a, mir-21, miR-16 and mir-181b-163–71.
In the quantitative proteomics with L-NSC (Fig. 5a), ATXN2L, FXR1, and NPC2 were modulated. ATXN2L
is a paralog of Ataxin 2, a protein that causes spinocerebellar ataxia type 272. It has been shown that ATXN2L is
functionally similar to Ataxin 2 with respect to RNA metabolism and also plays a role in the regulation of stress
granules and processing bodies in mammalian cells73. Overexpression of FXR1, a member of the Fragile X-related
family of RNA-binding proteins, has been associated with suppression of cellular senescence and cancer74. NPC2
regulates the transport of cholesterol through the late endosomal/lysosomal system and mutations in this gene
have been associated with Niemann-Pick disease type C2, a disease with a broad range of visceral, neurological
and psychiatric clinical presentations75.
In the quantitative proteomics of S-NSC (Fig. 5b) many more genes transcripts were modulated. Some of
particular interest are shown in Fig. 5b as follows: WDFY1 and PPP4C, two proteins known to modulate NFκB
activity, a key factor to control parasite infections, were downregulated in infected S-NSC (Fig. 5b). WDFY1
induces TLR3- and TLR4-mediated activation of NFκB and the production of type I interferons and inflammatory cytokines76, while PPP4C is the catalytic subunit of protein phosphatase 4, a protein implicated in the
activation of NFκB-mediated transcription77. This strongly suggests that T. gondii inhibits the human host NFkB
pathway at multiple levels in addition to promoting p65 degradation through the virulence factor ROP 1878.
Another two proteins, UBE3A and USP8, involved in protein ubiquitination, were also downregulated in infected
S-NSC (Supplement B: Table S15). Interestingly, deubiquitin USP8 regulates the turnover of the epidermal growth
factor receptor (EGFR) and its hyperactivation has been associated to constitutive EGFR-signaling leading to
corticotroph tumorigenesis79. USP8 also regulates parkin-mediated mitophagy, a process believed to be central to
the pathogenesis of Parkinson’s disease80, 81. Loss of function of the HECT-type E3 ubiquitin ligase UBE3A leads
to Angelman syndrome, characterized by microcephaly, severe developmental delay, ataxia, seizures, and happy
disposition82. Decrease expression of UBE3A has also been observed in Rett syndrome patients83. Within the
proteins that were upregulated during S-NSC infection, was eEF1A2, a translation elongation factor that has been
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Figure 9. Cluster deconvolution uncovers six clusters of protein-protein interactions effecting brain functions
and circuitry. STRING192 analysis of the brain infectome was carried out to elucidate protein-protein interaction
networks modulated by parasite infection (see Supplement B: Table S6). STRING analysis was performed on
a dataset composed of human susceptibility genes and biomarkers identified from patients with congenital
toxoplasmosis (CT, panel e) or plus a collection of genes differentially expressed in L-NSC infected with
type I parasites (panel a), type III (panel b), type II (panel c) or all strains (panel d). Six distinct clusters were
visualized from the integration of genetics, biomarkers and L-NSC expression data (panel e) in which clusters
1–3 radiate from NEDD8 (dashed circle, panel c,d), a central node modulated during Type II infection (panel
c). The genetics and biomarkers generated clusters 1a and 1b that were further expanded with connections to
genes modulated in Type I-III infectomes (panel a–c). Clusters 4 and 5 do not interact with NEDD8 (panel
c and d). Panel f shows a detail of the genes belonging to the odorant receptor cluster 5 that are perturbed in
L-NSC infected with T. gondii type I (Type I), II (Type II), III (Type III) or all three types (Type I-III) plus the
sum of genes modulated in S-NSC infected with types I, II and III parasites (Total). In panels a-e edge thickness
indicates confidence of interactions, with thin edges having middle confidence combined scores and thick edges
high confidence combined scores, as defined by STRING. In panel f, edge color represent interaction evidence
source as defined in STRING: light blue, curated database; yellow, text mining; purple, protein homology. Note:
odor attraction of mice and chimpanzees to cats56, 126.
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Figure 10. Deconvolution of brain infectome by disease correlation. The 3rd deconvolution approach of the
total brain infectome predicts correlation between T. gondii infection and common neurological diseases using
IPA disease and function tool (see Supplement B: Table S10A,B). (a) Grouping of disease annotations included
p-value and group size. The 4 disease groups are detected for all Type I, II and III infections. (b) Alzheimer
group included Alzheimer’s disease, tauopathy and amyloidosis annotations. IPA Canonical analysis indicates
this disease gene network is mediated by signaling pathways of adaptor protein 14-3-3 (7 genes), retinoic
acid receptor LXR/RXR (7 genes), tumor suppressor protein p53 (7 genes), cytokine IL-17A (5 genes) and
glucocorticoid receptor (13 genes). (c) Movement disorders. This entails predictions for movement disorders,
disorder of basal ganglia, neuromuscular disease, dyskinesia and Huntington’s Disease. IPA canonical analysis
of this gene network indicates signaling pathways mediated by G-Protein coupled receptor (13 genes), by cAMP
(10 genes), transcriptional regulator 14-3-3 (7 genes), cytokine Endothelin-1 (8 genes), polypeptide hormone
relaxin (9 genes) and corticotropin releasing hormone (8 genes). (d) Epileptic disorders pathways for seizures,
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seizure disorder and epileptic seizure. IPA canonical analysis of the 81-gene network indentifies top-ranking
signaling pathways that are associated with retinoic acid receptor (6 genes), endothelin-1 (6 genes), Gaq protein
(5 genes) and corticotropin releasing hormone (5 genes). (e) Cancer group. This illustrated mechanisms of
cancer, malignant solid tumor, abdominal neoplasm, abdominal cancer, urogenital cancer and genital tumor
that are potentially activated in the infected brain. The top 10 canonical pathways (Supplement B: Tables S8,9)
reveal important mechanisms that may potentiate cancer development in the T. gondii infected brain, such as
Wnt/Ca + pathway (14 genes) and role of IL-17A in arthritis (14 genes). Wnt/Ca + pathway annotation contains
6 frizzled class receptors (FZD2, FZD3, FZD4, FZD5, FZD8, FZD9) and receptor tyrosine kinase-like ROR1.
Not shown in diagram is the association with the schizophrenia 19-gene network: ABAT, ABCB1, ADRA1D,
ANK3, APOL1, CHRNA5, CHRNA7, E2F1, EGR3, EGR4, GAP43, GRIN2A, HOMER1, IL6, PMP22, PTGS2,
SCG2, SOD2, TMTC1.

proposed to play a significant role in tumorigenesis and as an anti-apoptotic factor84–86 (Table S15). Pathways of
cell death, TOR, protein transport/localization, RNA splicing, alternative splicing, oxidation reduction, vesicle
mediated transport, iron homeostasis, glucose metabolism are noteworthy in this proteomics analysis.
We found it remarkable that we identified serum biomarkers in the ill children compared with those who
were well (Fig. 6a–c). In considering these biomarkers in serum, three of those miRNAs, mir-17, mir-18b and
mir-19a, are all encoded by the miR-17-92 family of miRNA clusters that modulate a number of protein-coding
genes implicated in apoptosis, cell proliferation and angiogenesis87 (Fig. 6d). One of these miRs88, mir-17, is
over-expressed in Human Foreskin Fibroblast cultures infected with the RH strain of T. gondii89. Also noteworthy, mir-124 associated with neurodegeneration90, was increased in sera of the three ill children (Fig. 6b,c).
In addition, proteomics identified that ill children compared with their paired healthy controls had increases
or decreases in certain serum proteins. Elevated proteins included clusterin (CLU)91–93, serum amyloid
P-component (APCS)94, 95, and oxytocin(OXT)96–99 (Fig. 6d,e)91, 92, 95, 100–106. PGLYRP2 (Peptidoglycan recognition
protein 2, with N-acetylmuramoyl-L-alanine amidase activity), that degrades an innate immunity recognition
factor for peptidoglycans, was decreased in three of the ill children in the pairs (Fig. 6d). Apolipoprotein A1 also
was decreased in the ill children (Fig. 6). These proteins are known to be associated with neurodegeneration.
Specifically, clusterin is a chaperone which is increased in neurodegenerative diseases. It aids protein folding
of secreted proteins, with three isoforms that are differently involved in pro- or anti-apoptotic processes. Thus
this protein is involved in many diseases where there is oxidative stress including neurodegenerative diseases
and aging. It is associated with Lewy bodies in Parkinson’s disease, with the pathology in Alzheimer’s disease
and multiple system atrophy, Cerebrospinal fluid levels of clusterin may reflect pathology in neurodegenerative
disease. Amyloid P is in amyloid fibrils and protects them from degradation, thus contributing to neurodegeneration in Alzheimer’s disease94. It is also an acute phase reactant. Oxytocin was present in the sera of the ill boys.
Oxytocin diminishes inflammation, decreases anxiety, increases trust and empathy and mutations have been
associated with autism spectrum disorder96–99. Hypothalamic cells produce oxytocin which is then secreted into
the bloodstream by the posterior pituitary gland96–99. Secretion occurs when there is electrical activity, excitation,
of hypothalamic neurons96–99. These findings suggest active brain destruction by the parasite or the response to
it. These circulating miRNAs and proteins might prove clinically useful biomarkers to identify active toxoplasmic
brain (or possibly retinal) disease if confirmed with more children’s sera correlated with their clinical findings.
Key upstream regulators were identified as shown in Figs. 7 and 8. Descriptions of target and upstream regulatory genes analyzed for L-NSC, cohort genetics and cohort biomarkers considered together are illustrated in
Fig. 7. Key regulators we have found herein have been demonstrated to have significance in earlier work with
other cell types: Those known empirically include HIF1α/VEGF107, 108 and others such as EGFR109 (Fig. 7; Details
in Supplement B Table S7). IPA annotations of the total brain infectome and upstream regulatory bundle includes
core (Supplement B: Table S7) and comparison (Supplement B: Table S7) analyses of target genes, upstream regulators and both. The convergence of the genes, biomarkers, trancriptomic data, proteomic data on the upstream
regulators seen in this orbital diagram makes a model of the infectome which can be further empirically tested.
T. gondii molecules which modify them then can be identified. Upstream regulatory genes such as JUN, MYC,
EGFR, and VEGF110 provide examples of genes already known to be modulated by specific parasite proteins in
other cell types109, 111–113. The biologic relevance of this finding for humans is evident from the observation that
VEGF is very important in choroidal neovascular membranes that occur in clinical toxoplasmic chorioretinitis.
These resolve when treated with antibody to VEGF administered in conjunction with anti-T. gondii medicines108.
Upstream regulatory genes contributing to the signature pathways with important biologic impact were
compared when both L-NSC and S-NSC transcriptomic and proteomic data were analyzed together (Fig. 8).
Noteworthy upsteam regulators were identified. For example, fibroblast growth factor114 and its receptors (e.g.
FGRR1115), TGF-β, as well as the, ERK genes, PI3K, FoxOs116, and GM-CSF47, 117 are all involved in developmental
and adult neurogenesis. Both TGF-b118 and PI3K/Akt119 are involved in ROS and inflammation-related actions
during normal and pathological neurogenesis. In addition, TGF-β has been implicated in normal neural stem/
progenitor cell growth and differentiation, as well as in cancer stem cell-mediated gliomagenesis120. Likewise,
ERK signaling121 is involved in normal neural stem/progenitor cell fate choice during development. Another stem
cell pathology involving PI3K/PTEN122 has shown that altering this pathway can result in interneuronal dysplasia
and leukodystrophy as a result of altering neuronal and oligodendrocyte differentiation. All of these abnormal
neurogenic phenotypes were present in the infected adult human neural progenitor cell population studied.
Cluster protein interactions of L-NSC total infectome provided profound insight into pathogenic mechanisms (Fig. 9). The functional clusters included cellular movement and migration important in mechanisms
of immune and endocrine signaling, leucocyte migration, parasitism of lipid metabolism, ubiquitin-mediated
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Figure 11. Phenotypes in NSC demonstrating functions that are biologically important empirically. NFkB (left
panel): T. gondii (I, II, III) infection of S-NSC alters localization of p50-NFkB(red) and Stat 3 (second panel,
red): SAG1 (Green), Hoechst (blue); T. gondii, in NSC, expresses or alters host cells’ neurotransmitters. Tyrosine
Hydroxylase (red) in the infected NSCs that synthesizes dopamine is present in T. gondii (middle panels 40X,
60X). This is further exemplified in the furthest right panel by a dopamine-like immunostaining pattern in
the parasite (green). The red arrow in the dopamine-like staining image points to a host cell dense perinuclear
distribution of label. This suggests potential to influence neurotransmission in human NSC. This could
contribute to abnormal circuitry function as seen in mice and as occurs in epilepsy in some persons5, 6. These
experiments for immunostaining each of these molecules were performed at separate times, not simultaneously.

protein degradation in cell cycle control, and hijacking protein synthesis in the cell cycle, all clustering around
NEDD8123–125. As with ubiquitin and SUMO, NEDD8123–125 is conjugated to cellular proteins after the C-terminal
tail is processed. T. gondii tachyzoites thereby alter host cell protein stability and degradation, potentially contributing to ER “stress” and the misfolded protein response associated with neurodegeneration. Other clusters
include modulation of brain ATP production by mitochondrial oxidative phosphorylation. Another cluster shows
effect on olfactory receptors (Fig. 9) suggesting a mechanism whereby parasites alter host sense of smell as seen
in attraction of rodents and chimpanzees to cat urine56, 126. Parasitic modulation of these essential functions of the
brains could lead to a wide range of diseases, including those discussed below (Fig. 10).
One NSC phenotype suggested by our genetics and omics analyses led us to study phenotypic effect of T. gondii isolates on NFκB in S-NSC with IFA (Fig. 11). Effect on NFκB noted in murine cell lines, macrophages and
human fibroblasts and primary monocytes by others34, 36 were found mediated by Type II parasite dense granule
protein (GRA) 15, whereas we found T. gondii infection of primary human neuronal stem cells by all three strains
alters localization of NFκB (Fig. 11a). In other cell lines, STAT3 localization was modulated only by parasite Type
I ROP16127–129. This is similar, but not identical, to the nuclear translocation of STAT3 in our human neuronal
stem cells, which was increased most, but not exclusively, by the Type I strain. There was some similar effect for
Type II and III strains (Fig. 11a). Effects on such cytokine signaling pathways have potential to contribute to
maternal cytokine effects130 on fetal brain.
Another phenotype we selected for study included presence and localization of neurotransmitters (e.g., dopamine) and an enzyme in the brain involved in synthesis of this neurotransmitter, tyrosine hydroxylase. As shown
in Fig. 11, we found T. gondii affects both dopamine and tyrosine hydroxylase and T. gondii tachyzoites contain
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dopamine. Disruption of neurotransmission is associated with epilepsy5, 131. Alteration of neurotransmitters is consistent with association studies of seropositivity and human epilepsy131–134, and three separate studies of mice4, 5, 131.
These results are consistent with theories of T. gondii’s effects on reward pathways and depletion of serotonin by
precursor tryptophan starvation9, 135, 136. These findings concerning neurotransmitters may support alterations
of infectomes caused by the parasite affecting behavior, but these are predictions based on putative mechanisms
observed in cells in tissue culture and remain to be confirmed empirically with experiments in vivo.
In other diseases, such as certain genetic diseases with repetitive DNA sequences, alternative splicing or
mis-coding of transcripts can lead to truncated or misfolded proteins that are central causes of neurodegenerative
diseases137. Perturbing genes associated with the misfolded protein response, and protein degradation seen in the
IPA analyses, as well as inflammation are mechanisms whereby T. gondii may contribute to neurodegeneration,
alterations of cell cycle/replication and death, and epilepsy4, 133, 134, 138 (Figs 10 and 11).
When we place our findings presented herein in the broad context of diseases and mechanisms of specific diseases, our work indicates T. gondii can cause a dominant alteration of the cell cycle and opposing regulation of cell
growth and death. For example, as discussed above, in infected L-NSC, transcriptomes also showed that parasites
modulate pathways of cell death, apoptosis and neddylation. Modulation in p53 signaling, ribosomes, amino acid
metabolism, axon guidance, JAK-STAT, TGF-β, and cell cycle are especially noteworthy in the KEGG pathways
for S-NSC (Fig. 2c). Transcriptomic analysis of L-NSC reveals pathways associated with Alzheimer’s, Parkinson’s
and Huntington diseases and disruption of oxidative phosphorylation. Also alternative splicing pathways which
might cause protein misfolding and neurologic diseases are affected (Fig. 5). Transcriptomics, proteomics, and
cluster deconvolution identified alterations in neddylation and ubiquitination key in clearing misfolded proteins, neuronal cell viability, and synaptic plasticity (Figs 3–5, 9). We are investigating whether T. gondii causes
alternative splicing which can be a central cause of protein misfolding, neurodegeneration, and other complex
diseases137.
Although there are literature reports of associations between T. gondii seropositivity and schizophrenia in
individual studies and in a meta-analyses of 38 studies139, there is no proven causality. An increase in dopamine
metabolism is one possible pathologic mechanism140, 141. We detected dopamine and tyrosine hydroxylase immunostaining in the cytoplasm of T. gondii tachyzoites (Type I, II, and III) in S-NSC (Fig. 11). Alteration in dopamine neurotransmission has wide implications in behaviors and diseases, including epilepsy, neurodegeneration
and movement disorders142. However, we do not identify any congenitally infected persons or their mothers with
schizophrenia in our NCCCTS cohort (unpublished observations). Genetics and epigenetics of neuronal stem
cells may be derived from donors who are not predisposed to schizophrenia. Primary cultures of NSC were temporal lobe tissues transected from patients who have epilepsy.
Cancer is the largest disease correlate to our T. gondii brain infectome. One explanation may be relative
robustness of cancer research in comparison to other diseases in literature-based analyses. Some population
studies show correlation with brain cancer. There are anecdotal descriptions of lymphomas developing in eyes
of those with recurrent Toxoplasmic retinal disease143, 144. Targeted genetics studies of these T. gondii induced
cancer genes and pathways might reveal higher penetrance. A strong argument for a T. gondii-cancer link is long
known protection against tumor cells in murine models145. Recently, injection of attenuated, non-replicating
parasites increased long-term survival of mice with melanoma146, pancreatic147, and ovarian148 cancers by stimulating high-level expression of co-stimulatory molecules CD80, CD86, IL-12, and tumor antigen specific CD8 + T
cell populations and increasing cytolytic capacity of activated macrophages149. T. gondii may effect control of
tumor growth and clearance through a network of 1,178 genes we have identified. Furthermore, our data may
illuminate likely ways T. gondii may affect cancer stem cells, including stemness pathways of Wnt, TGF-β, STAT,
among others150 and potential associations with Alzheimer’s disease. Some population serologic studies show
conflicting correlations for151, 152 and against153, 154 T. gondii as a risk factor of Alzheimer’s disease or memory
impairment. The parasite, however, inhibits neuronal degeneration as well as learning and memory impairments
by immunosuppression in a murine model of Alzheimer’s disease155. T. gondii causes epilepsy131, possibly by altering GABAergic signaling6. Our analysis provides the systems map to study these correlations and applications of
T. gondii as an immunotherapeutic tool.
Olfactory dysfunction is reported in Alzheimer’s disease and schizophrenia156. T. gondii increases cat predation of an infected rat by altering neural activity in limbic brain areas to block innate aversion of rats for cat
urine. Infected chimpanzees lose their innate aversion towards urine of their natural predator, leopards126. There
is a report that T. gondii might alter olfactory preferences in humans157. Our cluster deconvolution discovered
12 olfactory receptors in humans modulated by the brain parasite possibly causing olfactory preferences and
dysfunction.
Only a subset of people with T. gondii infection, at the outset, have some of the diseases, like epilepsy or
malignancy, that share the alterations in the signature pathways we identified. Our data indicate these signature,
shared, molecular/cellular pathways, including inflammation, protein misfolding and mis-splicing, are altered by
T. gondii. We found that effects differ in some cases for parasites with differing genetics and cells of different types
or from different people. Our results provide insight into mechanisms whereby this parasite could cause these
associated diseases under some circumstances. We show that tachyzoites, the rapidly growing form, can cause
these158 alterations. In vivo this parasite interconverts from a dormant bradyzoite phase to an actively replicating
tachyzoite phase and back again. This interconversion may be relevant to associations we recognized. Biomarkers
we found were in ill children with new seizures and the two where we looked for this had reactivation of infection
with activity documented at the time. In a separate parallel analysis of dormant parasites that form definitive
cysts in vitro, similar pathways also were altered159 KEGG and GO analyses159 demonstrated a bradyzoite phenotype organism, called EGS, affects pathways involved in Alzheimer’s, Parkinson’s and Huntington’s diseases,
splicing, and oxidative damage159. Thus, both tachyzoites and bradyzoites perturb critical host signaling pathways
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in common with those perturbed in epilepsy, neurodegenerative diseases, motor diseases including movement
disorders, and brain cancer.
In neurodegenerative diseases and cancer, we have also shown glioma-initiating cancer stem-like cells possess an altered stem cell/developmentally regulated gene and protein mutanome160–163. An Adult Human Neural
Progenitor Cell (AHNP)49, has been suggested to be susceptible to chronic microenvironmental inflammation
in Parkinson’s Disease where it exhibits aberrant growth and differentiation164; in Alzheimer’s165, other neurodegenerative diseases and brain cancer. There are common growth-related programs and mutanomes in astrocytes
and neurogenic astrocytes166 that are at-risk for transformation during chronic inflammation. Altered levels of
cytokines and other immune- and inflammation-associated pathways, following T. gondii infection, have potential to support neurodegeneration and neoplastic transformation. It is notable that Zika virus infections also have
a profound destructive effect on neuronal progenitor cells167 that share a normal or cancerous neuropoietic (i.e.
persistent neurogenic) role during brain development and in the adult brain, including in the hippocampus168, 169.
We have shown that pathology in this cell population is also involved in epilepsy, memory disorders, and autism
in an interactome based on the literature. Carter et al. described similar overlap in neurologic susceptibility genes
and those T. gondii modulates, based on a literature analysis. This created an interactome of T.gondii infection
and genes implicated in a variety of neurologic and other diseases9. These diseases included multiple sclerosis,
neurodegenerative diseases, epilepsy, and malignancies9. Overlap in Carter et al.’s analysis with those genes and
pathways that T. gondii perturbs is striking9, although it is possible that they all involve the same pathways without
T. gondii causing the diseases. A large data analysis of insured U.S. patients revealed the same associations with
these diseases without clear directionality10.
All of these findings together support the notion that the dormant parasite, which sometimes interconverts to
active tachyzoites when cysts rupture, and are present in chronic T. gondii infection in the brain of 2 billion persons, also has potential to contribute to these disease pathways. We identify some of the same mechanisms with
tachyzoites. There is growing evidence for central nervous system transcellular spread of toxins, viruses, lectins
and macromolecules including pathological proteins and nucleic acids. This serves to transmit such infectious
elements170, 171 to naïve cells in neurodegenerative diseases (e.g., Parkinson’s and Alzheimer’s diseases) and cancer.
In these diseases particular neural sites and associated circuitries are hijacked and also affect the same neural
stem/progenitor cell studied here. We found in primary, T. gondii infected human neuronal stem cells these circuitries are altered in pathways of neurodegeneration, motor disease, movement disorders, epilepsy, malignancy
and in odorant receptors. Neddylation, ubiquitination, alternative splicing, cell replication, and autophagy are
altered, among others. These alterations provide some predicted mechanisms for the various clinical disease associations that also have been noted by others51, 138, 172–181.
Human chronic diseases are a complex interplay of genetic and environmental factors9, 136, 182–184 (Figs 1 and 10)
requiring modified approaches to reconstruct their multifactorial etiology and cascades of developmental-plasticity
mechanisms in precipitating disease. Human brain parasitism by T. gondii provides a model and template to examine development of brain diseases. This work provides a systems roadmap to design medicines and vaccines to
repair and prevent neuropathologic effects of T. gondii infection of the human brain. Further, our original template
provides a novel method to integrate multiple levels of intrinsic and extrinsic factors highlighting a way to unravel
complexity in brain parasitism, toxoplasmosis specifically, and other complex diseases.

Materials and Methods

Genetics. Patient cohort and genotyping. Our approach to understand T. gondii brain infection (Fig. 1a)
began with studies of families in which a child had congenital toxoplasmosis. We used clinical correlates
and genetics approaches with data from our cohort, the National Collaborative Chicago Based Congenital
Toxoplasmosis Study (NCCCTS). This program has diagnosed, treated and followed 246 congenitally infected
persons and their families continuously beginning in 1981, and thereafter in an ongoing manner through the
present. In this work, evaluations of affected persons took place from as early as gestation, when possible, through
older adulthood. These evaluations were/are at regular pre-specified intervals with standardized protocols, in
addition to other clinically indicated times. These evaluations occur in a single center in Chicago, performed by a
single, consistent group of physician evaluators11–39. In our earlier, published work11–39, this cohort and method of
analysis provided a powerful tool to identify genes and pathways causing susceptibility to toxoplasmosis (Table 1,
Fig. 1). In this earlier work, human susceptibility alleles of candidate genes for those in the NCCCTS were identified using Transmission Disequilibrium Testing (TDT).
As described in our earlier work, we used samples from patient-parent trios (a congenitally infected individual
and his/her biological parents) from the National Collaborative Chicago-Based Congenital Toxoplasmosis Study
(NCCCTS)12–14, 25, 31. We extracted DNA from peripheral blood mononuclear cells (PBMC) obtained from 149
patient-parent groups that were genotyped at 12 single nucleotide polymorphism tags (tag-SNPs) throughout the
specific gene. Tag-SNPs were then selected from the International HapMap Project, release 21 (http://www.hapmap.
org)12–14, 25, 31. This was done using a 10-kb flanking sequence on either side of the gene12–14, 25, 31. A minor allele
frequency (MAF) cutoff of 5% in Utah residents with Northern and Western European ancestry (CEU) and an r2
threshold of 0.8 were used12–14, 25, 31. Tag-SNPs were selected using the Tagger tool in the Haploview program12–14, 25, 31.
UNPHASED-2.404 https://sites.google.com/site/fdudbridge/software/unphased-2-404 was used for the allelic association analysis of 124 infected children in the NCCCTS cohort who had a confirmed presentation of clinical disease
involving the eyes and/or brain12–14, 25, 31. Hardy Weinberg Disequilibrium: The selected SNPs had an r2 threshold of
0.8, a minor allele frequency of >0.2, and were in Hardy-Weinberg equilibrium in the unrelated parents12–14, 25, 31.
For the genetic study, allelic association analysis was performed using conventional TDT to determine the linkage
disequilibrium (LD). LD is the nonrandom association of alleles at two or more loci12–14, 25, 31. It is essentially an
approximation of the existence of historical recombination between 2 loci12–14, 25, 31.
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NCCCTS informed consent and permissions. All studies involving human participants at the University of
Chicago were approved by the University of Chicago IRB. Informed consent was obtained from all participants
and/or their legal guardians. Informed consent to publish the image in Fig. 1b was obtained.
Statistical analysis for genetics. In the genetics study, allelic association was analyzed using a conventional transmission disequilibrium test (TDT), and P values were calculated using Haploview (http://www.broadinstitute.
org/haploview), where P values less than or equal to 0.05 were considered significant for association with disease.
P values are nominal and not Bonferroni corrected.
Analysis of Allen Brain Atlas Data for expresson of human toxoplasmosis susceptibility genes. The Allen Brain
Atlas (http://human.brain-map.org) was used to search for each gene of interest. The expression of each gene
was then visualized using the Allen Human Brain Atlas Brain Explorer 2 software (http://human.brain-map.
org/static/brainexplorer). The expression of each gene in each region of the brain is shown using a heat map
of the z-score for a specific probe for that gene. The z-score represents the normalized gene expression of that
probe across the entire brain. We used the following colors to illustrate gene expression: Red represents increased
expression and blue represents decreased expression.

Cells, Culturing and Microscopy. L-NSC Cells. All human brain tissues used in these studies were
obtained from the CPMC Neurosurgery Department, under an IRB approved protocol (Protocol #25.125-1). All
patients provided written consent stating that they allowed for their samples to be used for basic research. The
California Pacific Medical Center Institutional Review Board Panel#1 approved the tissue collection protocol,
including the patient consent forms (Current IRB Assurance NO: FWA00000921). Samples were de-identified
before being processed, to protect patient privacy. The L-NSC cell line was derived from the hippocampus tissue
removed from a patient with intractable epilepsy. Cells were characterized by immunofluorescence and found
positive for the neural stem and progenitor cell markers Nestin, glial fibrillary acidic protein or GFAP, Beta-III
tubulin or Tuj1 as a neuronal marker, and Olig 2 as a neuronal and glial progenitor cell marker. All experiments
were performed on passages 2–5 from the NPC culture. This was discussed previously in http://cancerres.aacrjournals.org/content/early/2011/09/06/0008-5nfk2.CAN-11-07. All methods were performed in accordance with
the relevant guidelines and regulations.
S-NSC Cells. IRB-approved and consented, from the University of Florida, S-NSC cells are adult human neural
stem/progenitor cells originally referred to as adult human neural progenitor cells or “AHNP” cells, and they were
cultured here according to the published protocol49. The culture conditions and nomenclature are shown in 2.
Human monocytic cell line. In vitro culture-adapted human monocytes, i.e., MonoMac6 cells185, were used.
MonoMac6 cells were seeded at 4 × 105/well in a 24-well plate in RPMI medium supplemented with 10% fetal
calf serum, 2.05 mM L-glutamine, 1 × nonessential amino acids (Sigma), OPI medium supplement (Hybri Max;
Sigma), and 1% penicillin-streptomycin (Thermo Fisher).

Toxoplasma gondii.

Toxoplasma gondii type I (GT1, RH), type II (Me49; Pru), and type III (VEG) maintained in HFF were used to infect the cells at a m.o.i. of 4, and incubated for 18 hrs. Extracellular Toxoplasma gondii were removed by washing with cold PBS before cells were harvested for total RNA extraction or IFA. Specific
parasites used in each experiment are specified in the results and figures.

Immunostaining and IFA. For immunostaining study, AHNP (S-NSC) cells were grown on glass cover slip
before infected with Toxoplasma gondii. 24 hours after infection, cells were fixed with paraformaldehyde and
standard immunefluroescent staining protocol was adopted for studying the localization of targets of interest,
including NFκB, STAT3, tyrosine hydroxylase, and dopamine. Antibodies utilized include: anti-NFκB p50 (Santa
Cruz Biotech, SC-7178); P-STAT3 (Y705), cell signaling (#91315); anti-tyrosin hydroxylase (Sigma, T1299); and
dopamine antibody (Novus Biologicals, NB120-1001).

RNA isolation, quantitation: RNA purification, RNA microarray and bioinformatics, RNA
sequencing and bioinformatics, miR sequencing. Isolation of RNA. Type I-II-III single celled organisms were grown in S-NSC, S-NDC or MM6. RNA was isolated and processed for sequencing as described. Below.
In all cases purified RNA had RIN scores >8. All experiments were done using biological replicates.

®

Affymetrix chip. Gene expression profiling was performed using the Affymetrix GeneChip Human Gene 1.0
ST Array (Affymetrix Inc., Santa Clara, CA). Total RNA was isolated using miRNeasy Mini Kit (Qiagen), and
converted to cDNA following the Ambion WT Expression protocol. Briefly, total RNA (250 ng) was used for 1st
and 2nd strand cDNA synthesis. cRNA was obtained by an in vitro transcription reaction, and was then used
as the template for generating 1st strand cDNA. The cDNA was fragmented and end-labeled with biotin using
the GeneChip WT Terminal Labeling kit. The biotin labeled cDNA was hybridized to the array for 16 hours at
45 °C using the GeneChip Hybridization Oven 640. Washing and staining with streptavidin-phycoerythrin was
performed using the GeneChip Hybridization, Wash and Stain Kit, and the GeneChip Fluidics Station 450.
Images were acquired using the GeneChip Scanner 3000 7 G and the GeneChip Command Console Software
(AGCC).

®

®

®

®

®

®

®

Differential gene and miRNA expression analysis. Total RNA samples extracted from uninfected human cell
cultures (controls) or from the same human cells infected with type I, II or III T. gondii strains for 18 hours, were
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treated with miRNeasy Mini Kit columns (Qiagen) following manufacturer instructions in order to separate
both mRNA and miRNA fractions for each condition. Thereafter, Illumina barcoded sequencing libraries were
constructed with TruSeq RNA Sample Preparation Kits v2 (Illumina) or NEBNext Multiplex Small RNA Library
Preparation Kit (NEB) for mRNA or miRNA sequencing respectively. All sequencing libraries were sequenced
using Illumina HiSeq. 2000 technology (100 bp single-end reads) and multiplexed in groups of 6 libraries per lane
for mRNA (total sequencing data per mRNA sample ~3 Gb) and 9 libraries per lane for miRNA (total sequencing
data per miRNA sample ~2 Gb). To quantify protein coding gene expression, CLC Genomic Workbench software (CLC Bio-Qiagen, Aarhus, Denmark) was used to map sequencing reads to the human reference assembly
(release GRCh38) and the T. gondii ME49 reference genome (ToxoDB release 13.0). Afterwards, to identify genes
that were differentially expressed in infected cultures compared to their respective uninfected control samples,
read counts per gene were analyzed with the R package edgeR using a generalized linear model likelihood ratio
test.
On the other hand, to assess miRNA differential gene expression, miRNA sequencing reads were first depleted
of adaptor and primer sequences and then mapped with CLC Genomic Workbench software to the human
reference genome assembly (GRCh38) using the miRNA annotations from miRBase v21 (www.mirbase.org).
Identification of human miRNA genes that were differentially expressed in infected host cells compared to their
corresponding uninfected controls was carried out with edgeR using a generalized linear model likelihood ratio
test.
For both mRNA and miRNA analyses, p-values were adjusted for multiple hypotheses testing using the False
Discovery Rate method. MDS plots and heat maps were generated with the plotMDS tool from edgeR and the R
tool heatmap. Differentially expressed genes in MM6 and NSC cell lines infected with Type I-II-III parasites were
identified under the criteria of 1% FDR and absolute log2-fold-change >1.5 (i.e. fold-change >2.8 and <0.35 for
up- and down-regulated genes, respectively).
Proteomics. The protocol was developed in 6 steps: (1) protein extraction with urea and SDS (2) protein digestion with Lys-C/ trypsin, (3) peptide labeling with isobaric iTRAQ reagents, (4) peptide fractionation by isoelectric point, (5) peptide identification and relative quantitation by tandem mass spectrometry with “higher energy
collision-induced dissociation” (HCD), and (6) bioinformatic analysis of mass spectroscopic data.
L-NSC Quantitative Proteomic using Multiplexed Isobaric Tandem Mass Tags. The protocol for Protein quantification, Protein extraction, iTRAQ labeling and mass spectrometry, Bioinformatics, and System Bioinformatics
was developed in six steps:
Step 1. Infected (RH, ME49, VEG strains of Toxoplasma gondii) and uninfected human NPCs were denatured
in 8 M Urea/ 0.4 M ammonium bicarbonate buffer, pH 8.0, and the urea soluble fraction was collected by centrifugation. Membrane proteins were extracted from the urea-insoluble pellet by adding 2% SDS to a final concentration of 0.125% (vol/vol) SDS. This sample fractions were then sonicated six times on ice with two to three
second bursts followed by a thirty second cooling period, using a Sonic Dismembrator 60 (Fisher Scientific). After
centrifugation this second supernatant was pooled with the first protein extract. The protein concentration in the
pooled urea/ SDS solubilized protein extracts was determined using a BCA assay (control, RH, ME49, and VEG
samples were 0.34, 0.49, 0.55 and 0.48 μg/uL, respectively).
Step 2. From this point, sample processing was performed in triplicate. For each sample, an aliquot containing
100 μg of total protein was added to Eppendorf tubes. A ten microliter aliquot of a solution of MassPREP Protein
Standard Mix (Waters, P/N 186004900) was added to each to serve as a process control. Next, proteins were precipitated using a cold acetone/TCA procedure. Samples were resuspended in 8 M urea/ 0.4 M ammonium bicarbonate buffer (pH 8). After reduction and alkylation with dithiothreitol and iodoacetamide, the samples were
diluted to 2 M urea/ 100 mM -ammonium bicarbonate, pH 8.0, final concentration. Lys-C was added at 1:200
(w/w) Lys-C:protein ratio and allowed to digest for 4 hours at 37 °C. Then Trypsin (Promega Gold) was added at
1:200 (w/w) and the digestion was allowed to digest overnight for approximately 16–20 hours total.
Step 3. After the proteolytic digestion, samples were desalted on a peptide macro trap (Michrom BioResources)
and dried by vacuum centrifugation. Steps given in Applied Biosystems’ iTRAQ reagent protocol guide (part#
4350831 Rev. C) titled Applied Biosystems iTRAQ Reagents: Amine-Modifying Labeling Reagents for Multiplexed
Relative and Absolute Protein Quantitation were followed for isobaric peptide labeling. First the samples were
dissolved in 40 μL of the dissolution buffer from the iTRAQ buffer kit. The tryptic peptides in each sample were
then labeled by the four tags (114: uninfected control; 115: RH; 116: ME49; 117: VEG) of a 4-plex iTRAQ kit.
Isopropanol was used to dissolve the iTRAQ reagents instead of ethanol. After labeling, the four samples for each
replicate were combined into a single Eppendorf tube. The samples were again dried by vacuum centrifugation
prior to removal of excess iTRAQ reagent by strong cation exchange chromatography, again as per the vendor’s instructions. Finally, the samples were desalted again using a peptide macro trap in preparation for OffGel
fractionation.
Step 4. The pooled labeled peptides were fractionated in-solution with an Agilent 3100 OFFGEL fractionator
following the manufacturer’s recommendations (Agilent Technologies)186, 187. A set-up was used to separate peptides according to their isoelectric point, consisted of a 13 cm IPG strip pH 3–10, and IPG buffer, pH3-10 (GE
Healthcare), and a 12 well frame set (Agilent Technologies). The unit was operated according to the Agilent’s
Operator Guide.
Step 5. OffGel Fractions were analyzed by nano-flow liquid chromatography tandem mass spectrometry (LC/
MS/MS). A nanoelectrospray source coupled an Ultimate 3000 LC system to a LTQ Orbitrap Velos Pro mass
spectrometer (Thermo Fisher Scientific, Bremen Germany). During the injection sequence, peptides were concentrated on a Dionex u-Precolumn Acclaim PepMap100 (C18, 5 um, 100 A, 300 um × 5 mm) and washed/
desalted for twenty minutes. Peptides were separated on a Zorbax 300 SB C18 (3.5 um, 150 mm × 75 um)
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nano-column from Agilent using a multi-step gradient spanning 100 minutes. Xcalibur was used to operate the
system in data-dependent acquisition mode. The ten most intense peptide ions detected by the orbital analyzer
were sequentially isolated for fragmentation in the HCD cell.
Step 6. We analyzed three analytical replicates for each of the four samples. Mass spectral data from the analysis of 12 IEF fractions were converted to MGF file formats using MassMatrix188, concatenated and submitted
as a single large MGF file for searches against NCBI human and Toxoplasma gondii databases using a Mascot
2.2 (Matrix Science) search engine189. The following search parameters were used: (i) enzyme, trypsin; (ii) one
missed cleavage allowed; (iii) fixed modifications, iTRAQ 4-plex, carbamidomethylation of cysteines; (iv) variable
modification, oxidation of methionine; (v) peptide tolerance, 10 ppm; and (vi) MS/MS tolerance, 30 ppm. Mascot
result files (.dat) were imported into Scaffold Q3 + (Proteome Software). Protein reporting thresholds were 95%
protein probability, 90% peptide probability, with at least two peptides per protein. Algorithms embedded in
Scaffold Q3 + were used to extract and to report the quantitative data collected during the iTRAQ experiment.

S-NSC- proteomics. Worksheet “Sample Proc” summarizes the sample prep process. From each flask,
~180–190 ug proteins were extracted and 50 ug were used for 8-plex iTRAQ analysis. Worksheet “Pep Ratio” is
the raw table listing relative ratios for all peptide identified in all 8 samples. The ratio should be 0.125 (1.000/8)
if one peptide/protein evenly distributes among 8 samples. Ratios of peptides from the same proteins are then
calculated to represent protein ratios. Worksheet “Ratio to Channel 0” includes a total of 4,367 identified proteins
with iTRAQ ratio. Note the protein ratios across 8 samples (4 conditions in duplicates) are raw data from mass
spectrometry and converted to ratios against Channel 0, i.e. Control sample 1. The data can also be normalized
using the factors in Column O in worksheet “Sample Proc”. Columns X-Z are average ratios in each infection
condition versus. average of controls. Worksheet “Prot with high score” has 3,359 proteins identified by more
than 1 peptide and with ProteinProphet probability >0.8 (=FDR < 1%). Among these 3,359 proteins with high
confidence, 10 protein concentrations increased by >2-fold in either of the 3 infected cells vs. controls, while 28
proteins decreased by >2-fold.
Human serum samples used in biomarker discovery. These data were obtained as follows: Three pairs

of children called pairs A, B, C were studied. They are described with additional information in the legend of
Fig. 4a, and in the methods, in each demographically-matched pair, one child had severe disease and the other
had mild or no clinical illness. Each child had serum stored from evaluations at the same ages, 3.5 years old (pairs
A and C). The first pair (A1/A2) were Caucasian children of the same ethnicity, originally primarily British, background, and similar demographics. The second pair (B1 and B2) were of Caucasian/Filipino ethnicity, dizygotic,
discordant twins who live in the same household. The third pair (C1 and C2) were children of Hispanic ethnicity
from the same geographic regions and with similar demographic characteristics. Each clinically well child was
identified because he was similar to the ill child. This was possible because we have in depth knowledge of the
clinical findings and demographics of the children followed in the NCCCTS. Thus, it was possible to identify
demographically matched well children for two (pair A and C) and a well twin for the ill twin (pair B). Serum
Collection for Children in the NCCCTS is as follows. These children have serum prepared from blood drawn at
each visit and the sera herein were obtained at a visit when new seizures were noted for ill children. The global
proteome and miRNAome changes in sera were analyzed with iTRAQ and miRNA qPCR panels.

Bioinformatics and Additional Systems Biology Analyses. The following analyses were performed at

the Institute of Systems Biology and J. Craig Venter Institute:

DEGs and DEmiR analysis of effect of cell type and parasite type. Differentially expressed genes and proteins
(iTRAQ) and human neuronal cells, culture conditions, and markers. A summary of DEG and DEmiRs. For
RNAs, lowly expressed RNAs were removed; threshold was defined in #3 & #4 f. Distribution of read counts
mapped to miRNAs. P < 0.01 and absolute log2-fold-change >1 (fold change >2 or <0.5). Relationship of
differentially expressed genes (DEGs) by cell line, relationship of DEGs by strain, relationship of differentially
expressed miRNAs (DEmiRs) by cell line, and relationship of DEmiRs by strain and functional enrichment
analysis included. For identified DEGs, GO Biological Processes were enriched with DAVID software v6.7. GO
Biological Processes with p-value < 0.01 and number of genes associated with certain GO term > = 5 summarized. KEGG pathway enrichment analysis is shown. For identified DEGs, KEGG pathways were enriched with
DAVID software v6.7. KEGG pathways with p-value < 0.05 summarized.

Upstream regulators for L-NSC and S-NSC transcriptomics and proteomics combined
(ISB). The upstream regulator analyses was performed to identify molecules regulating genes and proteins

identified from transcriptomic and proteomic data for L-NSC or S-NSC.
Genes and proteins differentially expressed in L-NSC or S-NSC were combined, respectively and used as an
input for the analysis. Based on the p-value < 0.01, 913 and 83 molecules were identified as upstream regulators
of genes or proteins differentially expressed in S-NSC and L-NSC, respectively. Using interactions between 22
common upstream regulators and their target genes/proteins, gene regulatory networks were constructed using
Cytoscape.
The Reconstruction-Deconvolution analysis was completed at BrainMicro LLC using Ingenuity Pathway
Analysis tool (IPA, Inc.)190, 191 and STRING v9.1 web-tool53. Allen Atlas and IPA used human T. gondii susceptibility genes. They show specific genes expressed in the brain. Additionally, it includes upstream regulators found
in IPA analysis. p-value of overlap < 5.0 × 10−3. Biomarkers for 3 ill children compared to well controls were then
added.
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STRING database provided analyses that are concentrated more on protein-protein interactions (Fig. 9;
Supplement 6). IPA provided the core analysis of network annotations, canonical pathways (Supplement B:
Tables S6, 9, 10), and disease-functions (Fig. 6; Supplement B:Table S6). In addition, IPA core analysis could
detect predicted upstream regulators of gene networks that were potentially not captured in the snapshots of
experimental design and data collection (Figs 1–6; Supplement B: S2, 7). In some cases when a larger dataset was
parsed into smaller networks, a secondary IPA core analysis was completed to identify the properties of the segregated datasets. Top-scored IPA analysis was also used to condense the large annotation prediction for comparison. In these cases, only the top 10–25 pathways/networks with lowest P-value, highest Z-scores are shown (e.g.,
Fig. 4, Supplement B: Table S3). Due to the large number of citations for function of genes and pathways, when
citations were not used, the information was obtained from the Ingenuity Knowledge Base (http://www.ingenuity.
com/science/knowledge-base). Cut-off p-value for each analysis were shown in each analysis.
We approached the Reconstruction-Deconvolution analysis without any preconceptions. Our deep understanding in parasitology and biological processes were used to understand the significant patterns emerged
with highest statistical values. Reconstruction of the brain infection used the template in Fig. 1. We examined the 1st ‘layer’ (susceptibility genetics) by IPA for 3 features: canonical pathways, upstream regulation, and
disease-functions. Each ‘layer’ of datasets was added sequentially in the following order of NSC transcript, NSC
protein and toxoplasmosis biomarkers. Each new composite layer was thorough analyzed for the 3 IPA features
to see the additive effects. Datasets were also segregated and analyzed separately by Type I, II and III infections.
The upstream regulators were further analyzed separately for canonical pathways and disease-functions. It was
important to have a complete, unbiased view of how each layer of data contributes and connects to each other.
Only selected, important observations were described in this report.
The total brain infectome included all 4 ‘layers’ and segregated according to parasite strains (Supplement B:
Table S7). Our Deconvolution strategy entailed 3 approaches. “Orbital Deconvolution’ was the visual design to
show connections between the 4 layers including the upstream regulators (Fig. 7) and portion of IPA analysis is
shown (Supplement B: Table S7). “Cluster Deconvolution’ utilized STRING to analyze meaning brain infectome
of L-NSC, meaning that S-NSC data was excluded, due to the number limit of STRING interactions (Fig. 9,
Supplement B: Table S6). We detected the 7 clusters based on visual detection of network maps. Genes for each
cluster was analyzed for the 3 IPA features to determine their properties. “Disease Deconvolution” was derived
from the IPA disease-functions analysis of the total brain infectome and graphically drawn in IPA (Fig. 10,
Supplement B: Tables S10A, B).
Analysis of Alternatively Spliced Genes. To identify potential candidate protein coding genes that were differentially spliced between infected and uninfected S-NSC cells, mRNA sequencing reads derived from infected
and uninfected S-NSC were mapped to the human reference assembly (GRCh38) with Tophat. Thereafter,
mapping data were processed with rMATS51 to identify candidate alternative-spliced transcripts. Predicted
alternative-spliced isoforms that were over- or under-represented in infected S-NSC cells compared to their
respective controls with an adjusted p-value < 0.1 (false discovery rate method) were kept for future analyses(Accession numbers in Supplement D).
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